The cost effective IVF strategies in assisted reproduction technology programmes (art) by Matsaseng, Thabo Christopher
THE COST EFFECTIVE IVF 
STRATEGIES IN ASSISTED 
REPRODUCTION TECHNOLOGY 
PROGRAMMES (ART) 
Thabo Christopher Matsaseng 
MBChB, FCOG (SA), Cert Reprod Med (SA) 
Dissertation presented for the degree of 
Doctor of Philosophy at Stellenbosch University 
Department of Obstetrics and Gynaecology 
Faculty of Medicine and Health Sciences 
Promoter:  Prof TF Kruger 
December 2016
DECLARATION 
By submitting this dissertation electronically, I declare that the entirety of the work 
contained therein is my own, original work, that I am the sole author thereof (save to 
the extent explicitly otherwise stated), that reproduction and publication thereof by 
Stellenbosch University will not infringe any third party rights and that I have not 
previously in its entirety or in part submitted it for obtaining any qualification. 
___________________________ 
Dr TC Matsaseng 
Date:  December 2016 
Copyright © 2016 Stellenbosch University 
All rights reserved 
Stellenbosch University  https://scholar.sun.ac.za
 
 
 
SUMMARY 
 
CHAPTER I 
Understanding the physiology of oocyte(s) recruited, selected and retrieved in a cycle 
of assisted reproductive technology (ART) is fundamentally important towards the 
development of the embryo with great potential for conception and live birth. This is 
discussed in detail.  
 
More important is the interpretation and utilization of the scientific evidence in this 
chapter to explore less expensive methods of optimizing oocyte quality in mild ovarian 
stimulation in vitro fertilization (IVF).  
 
CHAPTER II 
Clomiphene citrate (CC) is an inexpensive and safe drug that can be used alone or in 
combination with gonadotropins in IVF. 
 
Clinical outcomes in different IVF treatments using CC were reviewed and discussed 
in detail. The major concern regarding CC in ART is the risk of premature luteinizing 
hormone (LH) surge with subsequent detrimental effect on the oocyte quality. This 
issue is discussed with outlined strategies (inexpensive) to minimize the risk.  
 
CHAPTER III 
The effective methods to prevent premature LH surge in ART include gonadotropin 
releasing hormone antagonists (GnRHa) and gonadotropin releasing hormone 
agonists (GnRH). But these methods are expensive and unaffordable in resource- 
limited countries. We therefore performed a randomised controlled trial to evaluate a 
simple method of prolonged usage of CC as a strategy to prevent premature LH surge 
in ART treatment. The protocol is described in detail. The trial showed that prolonged 
usage of CC did not suppress premature LH surge in mild ovarian stimulation ART. 
But it motivated us to explore other inexpensive strategies for lowering the risk of 
premature LH surge such as pre-treatment with oral contraceptives, the use of 
tamoxifen and the use of progesterone during ovarian stimulation.  
CHAPTER IV 
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In our endeavour to explore strategies to make ART accessible, a public-private 
interaction (PPI) model is described in detail, highlighting different areas where the 
cost of IVF can be significantly reduced. They include infrastructure and equipment, 
personnel, ovarian stimulation protocol (detailed in Chapters II and III) and 
modification in the laboratory routine regarding oocyte retrieval.  
 
CHAPTER V 
This meta-analysis compared mild ovarian stimulation IVF with conventional treatment 
in order to counsel patients appropriately. The study showed significantly better 
outcomes in terms of live birth rates and ongoing pregnancy rates per started cycle, 
all in favour of conventional stimulation IVF, which therefore currently remains the 
preferred treatment of choice. 
 
CHAPTER VI 
Understanding the physiology of folliculogenesis has made it possible to integrate mild 
ovarian stimulation in our unit ART programme at a low cost.  (Chapter I) 
 
Reassuring clinical outcomes of CC in ART also motivated the unit to maintain low 
cost of treatment with the use of safe and effective medication. (Chapter II)  
 
The finding that prolonged usage of CC does not reduce the risk of premature LH 
surge has also allowed the unit to maintain the old protocol of 5 days’ use, but 
motivated us to explore other inexpensive methods. (Chapter III) 
 
The PPI model certainly managed to make ART treatment accessible to subfertile 
couples that would have never had a chance to be proud parents. (Chapter IV)  
 
Because this model is feasible and can be implemented at a reasonably low cost, it 
presents a viable option to make ART accessible in resource-limited countries.   
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OPSOMMING 
 
HOOFSTUK I 
Dit is uiters belangrik om die fisiologie van oosiet(e) werwing, seleksie en onttrekking 
in ‘n geassisteerde reproduktiewe tegnologie (ART) siklus te verstaan om ‘n embrio 
met groot potensiaal vir konsepsie en lewendige geboorte te ontwikkel.  Dit word in 
meer detail bespreek. 
 
Meer belangrik is die interpretasie en gebruik van wetenskaplike bewyse in hierdie 
hoofstuk om goedkoper metodes te ondersoek om oosiet kwaliteit met matige ovariële 
stimulasie in vitro bevrugting (IVB) te verhoog. 
 
HOOFSTUK II 
Klomifeen sitraat (CC) is ‘n goedkoop en veilige middel wat alleen of in kombinasie 
met gonadotropiene in IVB gebruik kan word. 
 
Kliniese uitkomste in verskillende IVB behandelings met CC is ondersoek en in detail 
bespreek. Die grootste bekommernis rakende CC in ART is die risiko van voortydige 
LH styging met daaropvolgende nadelige invloed op die oosiet kwaliteit. Dit word 
bespreek met ‘n verduideliking van strategieë (goedkoop) om die risiko te verminder.  
 
HOOFSTUK III 
Effektiewe metodes om voortydige LH styging in ART te voorkom sluit gonadotropien 
vrystellende hormoon antagoniste (GnRHa) en gonadotropien vrystellende hormoon 
agoniste (GnRH) in. Hierdie metodes is egter duur en onbekostigbaar in lande met 
beperkte hulpbronne. Ons het dus ‘n gerandomiseerde gekontroleerde studie 
uitgevoer om ‘n eenvoudige metode van verlengde gebruik van CC te ondersoek as 
‘n strategie om voortydige LH oplewing in ART behandeling te voorkom. Die protokol 
is in detail bespreek. Die studie het bevind dat langdurige gebruik van CC nie 
voortydige LH styging met matige ovariële stimulasie ART onderdruk het nie. Dit het 
ons egter motiveer om na ander goedkoop maniere te kyk om die risiko van voortydige 
LH oplewing te verminder, soos vooraf behandeling met orale voorbehoedmiddels, die 
gebruik van tamoksifeen en die gebruik van progesteroon gedurende ovariële 
stimulasie.  
Stellenbosch University  https://scholar.sun.ac.za
 
 
HOOFSTUK IV 
In ons poging om metodes te ondersoek om ART toeganklik te maak, word die 
publieke-privaat interaksie (PPI) model breedvoerig beskryf met die klem op 
verskillende areas waar die koste van IVF aansienlik verminder kan word. Dit sluit in 
infrastruktuur and toerusting, personeel, ovariële stimulasie protokol (verduidelik in 
Hoofstukke II en III) en aanpassing van laboratorium roetine betreffende die 
onttrekking van oosiete. 
 
HOOFSTUK V 
Hierdie meta-analiese het matige stimulasie IVF met gebruiklike behandeling vergelyk 
sodat pasiënte deeglik ingelig kon word. Die studie het merkbaar beter uitkomste in 
terme van lewendgebore syfers en voortgaande geboorte syfers per aanvang siklus, 
almal ten gunste van gebruiklike stimulasie, getoon wat tans die behandeling van 
keuse bly. 
 
HOOFSTUK VI 
Om die fisiologie van follikulogenese te verstaan het dit moontlik gemaak om matige 
ovariële stimulasie in ons eenheid se ART program te integreer teen ‘n lae koste.  
(Hoofstuk I) 
 
Gerusstellende kliniese uitkomste van CC in ART het ook die eenheid motiveer om ‘n 
laekoste behandeling te handhaaf met die gebruik van veilige en effektiewe medikasie. 
(Hoofstuk II) 
 
Die bevindinge dat langdurige gebruik van CC nie die risiko vir voortydige LH styging 
verminder nie het ons eenheid in staat gestel om ‘n ou protokol van 5 dae gebruik te 
handhaaf, maar ons gemotiveer om ander goedkoop metodes te ondersoek. (Hoofstuk 
III) 
 
Die PPI model het beslis ART behandeling toeganklik gemaak vir subfertiele egpare 
wat geen kans sou hê om trotse ouers te word nie. (Hoofstuk IV) 
 
Stellenbosch University  https://scholar.sun.ac.za
 
 
Omdat hierdie model haalbaar is en dit uitgevoer kan word teen ‘n redelike lae koste, 
skep dit ‘n lewensvatbare opsie om ART toeganklik te maak in lande met beperkte 
hulpbronne. 
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CHAPTER 1: FOLLICULOGENESIS 
 
SYNOPSIS 
 
The quantity and quality of oocyte(s) recruited, selected and retrieved in a cycle of 
ART is fundamentally important to the development of the embryo with great potential 
for conception and live birth.  
 
Follicular development and folliculogenesis is a dynamic structural and 
endocrinological process that has to be well orchestrated by two-cell, two-
gonadotropin theory including FSH and LH together with steroidal hormones and non-
steroidal paracrine factors such as TGF-β superfamily and IGF systems. It is 
understood that the duration of the rise in FSH above a critical threshold determines 
the number of dominant follicles to be selected from the recruited cohort. However the 
exact mechanism on the way in which follicular reserve is controlled and how follicles 
enter this growth journey of recruitment and selection towards ovulation or atresia, is 
not well understood. Furthermore, the emerging evidence in support of multiple (two 
or three) antral follicular waves recruited in a menstrual cycle still needs to be 
evaluated for clinical relevance, especially in ART treatment cycles.  
 
The role of adjunct therapy in ART cycles to improve pregnancy outcomes lacks robust 
evidence to be recommended as routine co-treatment during ovarian stimulation.  The 
apparent significant benefit of other adjunct therapies has been shown in women with 
poor ovarian response, unfortunately leaving many questions unanswered when it 
comes to the effect of adjunct therapies in women with normal ovarian response.  
 
Understanding how the ovary functions as a unit is therefore very important in 
controlled ovarian hyperstimulation cycles. More so, investigating ways and strategies 
on how to improve the quality of oocytes retrieved per cycle is also crucial to improving 
ART success rates.  
 
Keywords: antral follicles, ovary, folliculogenesis, assisted reproductive technology, 
adjunct therapies 
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INTRODUCTION 
 
The art of folliculogenesis is crucial and fundamental in understanding the ovarian 
function for the purpose of menstrual disorder and infertility management. The ovary 
as the unit contains oocytes that may eventually lead to embryo formation and 
conception following the fertilization process. It also provides the steroid and protein 
hormones that are essential for ovarian and menstrual regulation [1]. William Harvey 
proclaimed “ex ovo omnia” – all things come from the egg – emphasising the 
importance of the ovary [2]. 
  
With all the knowledge acquired over the decades, the human ovarian follicular growth 
and regression remains a complicated physiological phenomenon for scientists and 
clinicians alike. The current knowledge is based on the synergistic use of histologic, 
endocrinologic and ultrasonographic modalities [3,4] including extrapolation from 
studies performed in non-human primates, farm animals and rodents [4]. More studies, 
particularly in human ovarian function, are therefore still required.  
 
Physiology of follicular development and oocyte maturation 
 
During the menstrual cycle the ovarian follicles undergo dynamic morphologic and 
endocrinologic changes. 
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Figure 1: Ovarian changes during menstrual cycle 
 
 
            (Adapted from Ezcurra et al.,2014, Reprod Bio Endocrinol, 12: 95) 
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Histologic studies of ovaries show that the entire duration of human folliculogenesis 
from the primordial phase to the pre-ovulatory phase is estimated to be approximately 
>175 days [5] and follicular development begins as early as the fourth month of the 
foetal life. [4] 
 
Figure 2 
 
Somatic cells originating from the primitive gonad (superficial epithelial cells, follicular 
granulosa cells, theca cells, interstitial cells and fibroblasts) surround the oogonia, 
forming a rudimentary ovarian follicle. 
 
Follicles containing oocytes arrested in the dictate stage of meiosis I constitute the 
ovarian follicular reserve and the number of follicles occupying this reserve is 
estimated to be approximately 7 million at 20 weeks of gestation and approximately 1-
2 million at birth [6]. Depletion of the ovarian follicular reserve begins during foetal life 
and continues throughout woman’s lifetime via process of follicular atresia [7]. The 
pre-antral follicles of 0.1 – 0.2 mm develop independent of gonadotropins support [4]. 
 
  
 
Primordial germ cells 
(Migrate from yolk sac endoderm to the gonadal ridge while undergoing mitotic division 
at this stage) 
 
 
At the gonadal ridge, the oogonia enter the first meiotic division 
 
 
Primary oocytes 
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Folliculogenesis – clarity on terminology [8] 
 
Recruitment used to describe: 
(i) Initial transition of primordial follicles from the resting pool into the pre-antral 
growth phase; 
(ii) Cyclic recruitment of a cohort of antral follicles of 2-5mm during the menstrual 
cycle; 
(iii) The preferential growth of the dominant ovulatory follicle.  The current 
understanding and acceptable description of recruitment is the emergence of 
a group or cohort of medium-sized (2-5mm) antral follicles [4]. 
 
Selection used to describe: 
(i) The recruitment of a cohort of 2-5mm antral follicles 
(ii) Preferential growth of a species – specific number of large antral follicles from 
the recruited cohort – dominant follicle selection. 
 The current acceptable description is the preferential growth of the dominant 
follicle from the cohort of recruited antral follicles [4]. 
 
Subordinate follicles, also known as challengers, ordinary or subdominants, 
compromise all follicles of the recruited cohort excluding the dominant follicle. 
 
Three theories of follicular recruitment [4] 
 
Continuous recruitment I 
Animal studies concluded that early antral follicle growth occurred continuously 
throughout the estrous / menstrual cycle, while human studies suggest that small 
antral follicles of ≤ 4-6mm are recruited to grow continuously at all stages of 
reproductive life independent of gonadotropin support. Cyclic increases in the number 
of antral follicles have been observed at regular intervals during the menstrual cycle 
of women [9].  
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Single recruitment episode II 
Histologic, endocrinologic and early ultrasonographic studies have demonstrated that 
a cohort of 2-5mm follicles is recruited from a continuous supply of antral follicles once 
during the menstrual cycle [10].  
 
Endocrinologically, following the regression of CL, oestradiol and inhibin falls as a 
result the circulating FSH increases. The rise in FSH is thought to be responsible for 
preventing atresia of a cohort of 2-5mm antral follicles. [10] Similarly to the notion of 
preventing atresia, is the concept that recruitment is induced by rising FSH [11].  
 
Inhibin B produced by granulosa cells in follicles of the recruited cohort acts in the 
endocrine manner to inhibit continued FSH secretion in the mid-follicular phase 
[12,13]. 
 
Inhibin A levels are low during the follicular phase but higher during the mid-luteal 
phase, suggesting that the CL is a source of inhibin A [13]. 
 
High oestradiol and inhibin A concentrations in the mid-luteal phase are thought to 
suppress FSH and thereby prevent the development of healthy follicles [14]. 
 
However, Pache et al. disputed the concept of a single increase in the number of  
2-5mm antral follicles during the late luteal or early follicular phases by showing that 
the mean number of antral follicles, AFC (2-5mm) was not different in the early 
follicular, late follicular and luteal phases [10,15]. 
 
AMH is produced by the granulosa cells of the primary, secondary, pre-antral and early 
antral follicles (≤4mm). AMH inhibits the initiation of primordial follicle growth from the 
ovarian reserve, thereby regulating the recruitment of antral follicles.  
 
Multiple Follicular waves III 
Multiple cohorts or “waves” of antral follicle recruitment have been described, 
suggesting that antral follicles may not only be seen in the late luteal phase [3,9,16].  
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Ultrasonographic studies have also demonstrated two waves of follicle development 
in women with regular menstrual cycles [9]. It is interesting to note that 68% of women 
exhibited two waves of follicle recruitment during the interovulation interval (IOI) while 
the remaining 32% exhibited three waves [4].  
 
Important research questions to answer are: 
a. When is the appropriate time to assess the AFC to predict response to ovarian 
stimulation – could it be any time of the menstrual cycle?? 
b. Can ovarian stimulation therapy be initiated at any time during the cycles? 
Including the luteal phase of the menstrual cycle? 
c. Innovative contraceptive designs?  
d. Do women with multiple follicular waves reach the menopause earlier or not? 
 
Another observation is the inverse association between the circulating FSH and the 
number of follicles in a wave, and this is consistent with age-related decrease in AFC 
and elevated FSH in women [17]. 
 
Theories on Follicle Selection 
 
Follicle selection is a process by which a single “dominant” follicle is chosen from the 
recruited cohort or wave for preferential growth [4,10,16]. It generally occurs in the 
early to mid-follicular phase of the menstrual cycle.   
 
Follicle divergence 
At the time of selection, the dominant follicle begins to “diverge” as it continues to grow 
while the subordinate follicles undergo atresia [18]. Divergence occurs when the 
dominant follicle reaches a diameter of approximately 10mm on day 6-9 of the follicular 
phase in women [10,16,18]. It is postulated that the future dominant follicle may 
contain more granulosa cells and FSH receptors, making it more sensitive to even low 
levels of circulating FSH compared to subdominant follicles, intra-ovarian manipulation 
[11].  
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Follicle dominance 
Once the dominant follicle is formed, it exerts morphological and functional 
dominance.  
 
High levels of FSH are required for the recruitment of a follicular cohort. The recruited 
cohort produces oestradiol and inhibin B from granulosa cells. They both suppress 
FSH, resulting “post surge” decline which is a crucial step in the selection process.  
 
The duration of the rise in FSH above the critical threshold determines the number of 
dominant follicles selected from the recruited cohort [19]. This phenomenon is termed 
the “FSH Threshold” or “FSH Window” or “FSH gate” [19]. During ovarian stimulation 
therapy, prolonging the FSH window allows multiple follicles to be selected [19]. 
 
On day 5-8 of the menstrual cycle the aromatase activity begin in the granulosa cells 
of follicles larger than 6-8mm, with the dominant follicle producing more oestradiol than 
other follicles in the cohort [20]. Elevated oestradiol further suppresses FSH to the 
detriment of subordinate follicles but favours the dominant follicle with a large number 
of FSH receptors. Furthermore, the oestradiol secretion will result in LH receptor 
formation on the granulosa cells of the dominant follicle, therefore becoming less 
dependent on FSH and more responsive to LH [21].  
 
Paracrine factors in folliculogenesis 
 
Transforming growth factors–β superfamily 
The TGF–β superfamily includes inhibin, activin, follistatin, TGF-β, BMP, GDF and 
AMH.  Oocyte and cumulus cells have a special communication through the paracrine 
and/or autocrine mechanism to regulate antral follicle development and oocyte 
competence [4]. 
 
The role of inhibin B produced by granulosa cells and subsequently decreasing FSH 
production prior to dominant follicle selection, is known from animal studies [22].  
Activin has been reported to be associated with an inhibitory effect on the LH-induced 
production of progesterone, preventing spontaneous luteinisation in mature antral 
follicles [23,24]. 
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In contrast, follistatin and inhibin A are associated with increased LH-induced thecal 
androgen production, which serves as a substrate for dominant follicle oestradiol [25]. 
Therefore a programmed and systematic transition from an inhibin B/activin follicular 
environment to a follistatin/inhibin A environment is critical for dominant follicle 
development in women [26]. 
 
Insulin-like growth factor system 
IGF I and II mRNA have been detected in the theca cells of the small antral follicles, 
but only IGF II mRNA has been detected in the granulosa cells of the dominant follicle 
[27], especially at the time of selection. IGF II and IGF I stimulate aromatase activity, 
oestradiol and progesterone production in human granulosa cells and promote 
androgen production in the theca cells of the growing dominant follicle [4]. In 
subordinate follicles IGF is sequestered by IGFBP-4, thereby inhibiting 
steroidogenesis in granulosa and theca cells, leading to atresia [28]. 
 
Pre-ovulatory follicle 
 
The dominant follicle may grow to a follicle of 16-29mm [9]. The ovulatory follicle grows 
at a rate of 1-4mm/day [10]. During the mid-follicular phase, the dominant follicle is 
associated with increased aromatase activity and a rapid rise in circulating and 
follicular oestradiol-17β [16]. Oestradiol production from the dominant follicle peaks 
the day before the LH surge (Fig. 1), providing positive feedback at the hypothalamus 
and pituitary to stimulate the surge of LH necessary for inducing ovulation [4]. 
Ovulation will therefore occur on average within 24hrs of the LH peak [29].  
 
Ovarian stimulation in assisted reproductive technology and folliculogenesis 
 
In COH cycles, the hypothalamus–pituitary–ovarian unit and the antral follicles are 
manipulated at the time of the selection process in the divergence phase [18,30,31]. 
 
The key question to be answered is: If the concept of multiple follicular wave 
emergences is understood and accepted, will it influence the strategies for 
synchronizing follicles in COH or the way the treatment is initiated [3]? Other authors 
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have proposed such change in the approach to treatment, especially in reproductive 
ageing woman, citing no risk of premature LH surge, and reduced cost of ART [3]. 
 
Oocyte quality and adjuncts in folliculogenesis 
 
Oestrogen administration  
Oestrogen administration for follicular synchronization has been evaluated with no 
overall benefit in improving ART outcomes [32,33]. The treatment would be initiated in 
the luteal phase, from day 20 of the previous cycle to day 2 of the following cycle at a 
dose of 4mg per day. The aim would be to lower the FSH levels during the luteo-
follicular transition in order to increase the number oocytes for retrieval, reduce 
cancellation rates and increase fertilization rates, making it the less expensive option 
versus the long GnRH agonist down regulation protocol [31]. 
 
Oral contraceptive pill 
It has been suggested that OCP pre-treatment in IVF cycles might be beneficial in 
improving ovarian response through inhibition of intrinsic gonadotropins before 
ovarian stimulation [34]. However, this was associated with poorer pregnancy 
outcomes even though there was a markedly reduced risk of ovarian cysts [35]. In a 
recent review the use of OCP pre-treatment in ART has been categorised as a 
promising intervention [36]. 
 
Androgen supplementation  
Androgens (DHEA, testosterone and androstenedione) exert their action mainly 
through ARs [37]. ARs are expressed in all cell types of the ovarian follicle including 
the oocyte, granulosa cells and theca cells [38]. 
 
The low ovarian reserve has been associated with impaired quantity and quality of the 
ovarian follicles [37]. A number of studies suggest that androgen supplementation may 
enhance fertility potential in women with a low ovarian reserve [39,40,41].  
The recommended dosage of DHEA of 75mg/day in women with a low ovarian reserve 
was associated with a high oocyte yield and significantly increased birth rates [39]. 
Furthermore it is suggested to be associated with lowering the risk of age-related 
aneuploidy [42] and miscarriages [43]. The exact mechanism is unclear but it is 
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suggested DHEA is a precursor for sex steroid hormones in the ovarian follicle and it 
may also induce FSH receptors in the granulosa cells [44]. DHEA also increases  
IGF I and decreases IGFBP-I, positively favouring follicular development [44]. Some 
authors do not believe the mechanism is responsible for the improvement in IVF 
treatment outcomes through the recruitment of more pre-antral follicles or very small 
antral follicles, as there was no change in AMH and inhibin B levels, but rather the 
rescue from atresia of small antral follicles as evidenced by an increase in AFC [45].  
In a review and meta-analysis that included three trials of 153 women in a transdermal 
patch of testosterone group and 112 in the control group, they found significantly 
higher live birth rates (RR 1.91, 95%CI 1.01 to 3.63), with no difference observed in 
the number and quality of oocytes retrieved [46].  
 
The limitation of evidence in androgen supplementation lay in the small sample sizes, 
lack of proper randomization and extrapolation from animal studies which might not 
be reproducible in humans [47,48]. This suggests the need for more trials on the role 
of androgens in ART outcomes and particularly in normal responders. 
 
Stimulation protocols 
Controlled ovarian hyperstimulation is an integral part of assisted reproduction with 
strong emphasis on the development of multiple follicles for retrieval of good quality 
oocytes for fertilization, implantation and overall live birth.  
 
The stimulation protocols have evolved over the past decades with the introduction of 
pituitary down regulation regimes (GnRH agonists and antagonists) to prevent 
premature luteinisation and reduce high cycle cancellation rates [49]. The current 
evidence has so far concluded that no one protocol is superior to another [49,50]. The 
long GnRH analogues however appear to be more effective in poor responder women 
undergoing IVF and the antagonists are associated with significant reduction in OHSS 
[36,51].  
 
With regard to different drug regimes, there is no difference in effect on overall LBR 
and clinical pregnancy rates [36,52,53]. Some authors have reported a potential 
concern with urinary hMG, namely that it possesses hCG that would lead to excessive 
LH-like activity resulting in premature luteinisation and reduced fertilization rates [54]. 
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However this concern has not been confirmed in robust literature and it will have to be 
evaluated in larger clinical trials.  
 
Luteinizing hormone supplementation 
According to the two-cell two-gonadotropin theory, the FSH and LH together with local 
steroidal and non-steroidal factors stimulate follicular growth and maturation, ovulation 
and the development of the CL [1]. Several studies have reported better oocyte and 
embryo quality, reduction in the apoptosis rate, and improved fertilization, implantation 
and pregnancy rates with overall improvement in the ART outcomes in women treated 
with r-hLH in IVF/ICSI treatment [55-58]. 
 
However, some authors did not find any benefit in terms of increased pregnancy rates 
[59,60]. The apparent overwhelming effect of LH supplementation is reported in poor 
responders with a reduced rate of early pregnancy loss, increased number of oocytes 
retrieved and significantly higher clinical pregnancy rates [60-62].  
 
In a recent Cochrane review, the use of r-hLH in ART cycles is categorized as a 
promising intervention, with more evidence still required [36].  
 
Glucocorticoids  
Glucocorticoids are thought to stimulate GH and IGF 1 during ovarian stimulation [63]. 
Keay et al found that low-dose dexamethasone co-treatment, 1mg/day from the day 
of initiation of gonadotropins until the night before oocyte retrieval, was associated 
with reduction in poor ovarian response, but the mechanism by which glucocorticoids 
alter the ovarian responsiveness remains unclear [63]. It has further been postulated 
that glucocorticoids may be used as an immunomodulator by lowering the natural killer 
cells to normalise the cytokine expression profile in the endometrium in order to 
improve implantation [64]. In a Cochrane review by Boomsma and colleagues, there 
was no clear evidence that the administration of peri-implantation glucocorticoids 
improved implantation rates and ART outcomes [64]. However, they further reported 
borderline statistically significant improvement in pregnancy rates in women 
undergoing IVF and not ICSI. The reason for this finding was unclear [64].  
 
Stellenbosch University  https://scholar.sun.ac.za
13 
 
Limited available evidence has shown improvement in ovulation rates, fertilization and 
pregnancy rates when glucocorticoids are used in combination with CC, versus CC 
alone [49]. Given the lack of good evidence, the role of dexamethasone as an adjunct 
in ART still needs to be investigated before it can be recommended as a routine 
treatment in ART treatments. 
 
Metformin 
There is no conclusive evidence that metformin before or during treatment of ART 
cycles improved LBR in women with PCOS. However it is associated with increased 
clinical pregnancy rates and reduced risk of OHSS [36,65,66]. 
 
Aspirin 
Low-dose aspirin is supposed to increase the ovarian and uterine blood flow with 
subsequent increase in ART outcomes, but this benefit has not been proven in terms 
of live birth and clinical pregnancy rates when compared with placebo or no treatment 
[36,67]. 
 
Growth hormone  
The use of a growth hormone as an adjunct therapy has been reported to be 
associated with significantly increased LBR in poor responders in ART treatment, 
therefore recognizing the intervention as effective in that regard [36].  
 
SUMMARY AND CONCLUSION 
 
With no reasonable doubt, many milestones have been achieved in ART [68], and the 
science of ovarian stimulation is certainly one of them. However, as we strive for better 
ART outcomes and yet being mindful of the possible complications such as OHSS and 
the increased cost of treatment, refined and robust knowledge on folliculogenesis is 
still necessary.  
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CHAPTER 2: CLOMIPHENE CITRATE IN ASSISTED REPRODUCTIVE 
TECHNOLOGIES: WHAT IS THE FUTURE? A NARRATIVE REVIEW 
 
SYNOPSIS 
 
Objective: To evaluate the role of clomiphene citrate (CC) alone or in combination 
with gonadotropins with/without antagonists in ART programmes.  
 
Design: Narrative review 
 
Search methods: We reviewed the literature involving the use of CC alone 
(publications after 1990) and CC in combination with gonadotropins with or without 
mid-cycle GnRH antagonists (publications after 2000) in IVF/ICSI cycles. The search 
was electronically using PubMed Central, Medline, and Embase and the reference 
lists of articles. Relevant conference proceedings and other articles were hand 
searched.  
 
Selection criteria and outcome measures: All studies that involved CC alone or in 
combination with gonadotropins with/without mid-cycle antagonists in IVF/ICSI were 
included. The following outcomes were measured: number of oocytes retrieved, 
number of embryos transferred, cryopreserved cycles, endometrial thickness, rates of 
premature LH surge (LH ≥ 10IU), clinical pregnancy rates, OPR and LBR. 
 
Main Results: A total of thirty studies were included in the review. There were nine 
studies in CC alone, of which three were RCTs. Twenty one studies involved CC in 
combination with gonadotropins, six no mid-cycle antagonist and 15 mid-cycle 
antagonist. Reported CPR in CC alone varied from 16% per cycle to 34% per ET. In 
CC plus gonadotropins cycles (without antagonists), CPR also varied from 14% per 
cycle to 42% per ET. The premature LH surge was as high as 30%. Cycles involving 
CC plus gonadotropins (with antagonists) reported LBR of 30-36% with no cases of 
premature LH surge observed.  
 
Conclusion: The current available evidence does suggest a CC + gonadotropin + 
mid-cycle antagonist protocol as an effective protocol with comparable LBR and OPR. 
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In addition, it is associated with a reduced risk of OHSS and lesser number of 
gonadotropins required. CC + gonadotropins without antagonists also appears to be 
a feasible protocol in a well selected group of patients, young and normal endocrine 
profile. The risk of premature LH surge may be minimised by pre-treatment OCP or 
prolonged use of CC during stimulation or simultaneous use of CC and gonadotropins. 
 
Keywords: Clomiphene citrate, premature LH surge, ART, mid-cycle GnRH 
antagonists, pregnancy outcomes 
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INTRODUCTION 
 
The primary objective of COH in ART is to achieve multi-follicular development in order 
to retrieve mature oocytes that are competent for fertilization and may possibly result 
in pregnancy and eventually a live birth.  
 
The long complex GnRH agonist and gonadotropin stimulation protocol is regarded as 
the gold standard regimen because it is highly effective in pituitary down regulation, 
thereby enabling synchronised development and the retrieval of a large number of 
oocytes per cycle with high pregnancy rates, fewer cancellation rates and better 
planning of treatment cycles [1]. 
 
However, this protocol is associated with increased cost of medication, increased risk 
of OHSS and a high order of multiple pregnancies [2,3]. 
 
Mild ovarian stimulation for IVF is defined as a procedure in which the ovaries are 
stimulated with gonadotropins and/or other oral compounds such as CC, with the 
intent to limit the number of oocytes obtained to fewer than seven [4]. They are 
currently being explored and receiving a lot of attention as an alternative strategy to 
minimise the risk of adverse events associated with complex conventional ovarian 
stimulation protocols. 
 
Available data show that mild ovarian stimulation lessens the patient’s discomfort [5] 
and is also associated with significantly lower doses of gonadotropins used per cycle 
[6,7]. But it is also associated with a low number of oocytes retrieved and embryos 
generated for transfer [7]. Of interest is that even though the number of embryos is 
lower in mild stimulation cycle, the proportion of chromosomally normal embryos is 
significantly increased [7]. The general disadvantages of mild ovarian stimulation 
include lower pregnancy rates and high cancellation rates per stated cycle [8-10].  
 
CC was the first agent to be used in ovarian stimulation for IVF in the early 80’s and it 
continues to be part and parcel of modern ART [11], particularly in mild regimens. Over 
and above known disadvantages associated with mild ovarian stimulation protocols, 
CC treatment is attributable to a 15-25% risk of premature LH that may result in 
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premature ovulation and loss of oocytes, and it also negatively affects the quality of 
oocytes and as a result, lowers the pregnancy rate [11,12].  
 
Other than effective but long and complex GnRH agonist protocols, several strategies 
are available to prevent premature LH surge, such as mid-cycle GnRH antagonist 
usage [12-14]. However, Tavaniotou et al. reported significantly high levels of LH 
concentrations despite the administration of a GnRH antagonist [15]. Similar findings 
were reported by Engel and colleagues [16].  
 
Hot flushes, lower abdominal pains, headaches and some psychic psychiatric 
symptoms have also been associated with the use of CC [17]. Furthermore, non-
specific birth defects were also observed amongst CC users [18], but a review by 
Gibreel et al. did not find any association with birth defects [19].  
 
The anti-oestrogenic detrimental effect of CC on the cervical mucus and the 
endometrium are postulated mechanisms resulting in poor pregnancy rates despite 
successful ovulation induction [20-22]. It is noted that in ART cycles involving the use 
of a CC/gonadotropins/mid-cycle antagonist versus a conventional long GnRH agonist 
protocol, there was no significant difference in the endometrial thickness (mm) 
between the two groups [23,24]. 
 
CC alone or in combination with gonadotropins have been suggested and provided as 
an alternative cost effective strategy for women with compromised ovarian reserve 
and poor response to conventional ovarian stimulation [24-26]. Therefore, because of 
the potential benefit in a selected group of patients, the well-known side effect profile, 
ease of administration and low cost results in CC remaining a useful agent in ovarian 
stimulation for IVF/ICSI treatment. 
 
We therefore reviewed the literature involving the use of CC alone (publications after 
1990) and CC in combination with gonadotropins with or without mid-cycle GnRH 
antagonists (publications after 2000) in IVF/ICSI cycles. 
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Design: Narrative review 
 
Search methods:  
We reviewed the literature involving the use of CC alone (publications after 1990) and 
CC in combination with gonadotropins with or without mid-cycle GnRH antagonists 
(publications after 2000) in IVF/ICSI cycles. The search was electronically using 
PubMed Central, Medline, and Embase and reference list of articles. Relevant 
conference proceedings and other articles were hand searched.  
 
We reviewed articles that reported the following outcome measures:  
 number of oocytes retrieved 
 number of embryos transferred 
 cryopreserved cycles 
 endometrial thickness 
 rates of premature LH surge (LH≥10IU) 
 CPR (cardiac activity at 7 weeks) 
 OPR (cardiac activity at 12 weeks) 
 LBR (birth of singleton healthy baby) 
 miscarriage rates (loss of pregnancy before 12 weeks of gestation) 
 number of cycles cancelled, and 
 total number of gonadotropins used.  
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Table 1, Part A: Clomiphene Citrate alone studies 
Study Design Study Intervention  Outcomes Conclusion Comment 
Saunders et al. 
1992 [39] 
Review 3377 patients undergoing 
IVF (1941) and GIFT 
(1436) 
CCtreatment cycle Miscarriage rate significantly 
higher in CC group (24.4% 
IVF; 23.0 GIFT) vs. (20.7% 
IVF; 17.9% GIFT) in GnRHa 
group 
 
Increased wastage 
due to CC or 
increased LH levels 
during 
folliculogenesis 
Old study with 
missing detail. 
       
MacDougall et al. 
1994 [27] 
Prospective 
Randomised 
30 participants 
n=14 no treatment 
n=16 CC 100mg day2-6 
CC vs NC Increased no of oocytes in 
CC (1.8±0.3) 
CPR (18% CC vs. 0% NC) 
Significantly higher PR with 
CC 
Cycles cancelled in NC 
10/14 (71%) 
 
High cancellation 
rates in NC 
Old data 
       
Gentry et al. 1996 
[30] 
Prospective 
Comparative 
128 patients but 84 
evaluated for endometrial 
thickness (ETs) 
CC CPR in different ETs 
3/15 (20%): >4mm <7mm 
13/41 (32%): > 7mm< 10mm 
7/25 (28%) in >10mm 
No significant difference 
ETs in CC-IVF 
should not be an 
exclusion criterion 
Comparable 
pregnancy rates  
Old study 
No p-values 
recorded 
       
LH=Luteinizing hormone, ET=Embryo transfer, E2=Oestradiol, TDS=three times a day, NC=Natural cycle, CC=Clomiphene Citrate, CPR=Clinical pregnancy 
rate, VEGF=Vascular endothelial growth factor, FF=Follicular fluid, OC=Oral contraceptive, hMG= human menopausal gonadotropin, PR = Pregnancy rates 
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Study Design Study Intervention  Outcomes Conclusion Comment 
Awonuga et al. 
1997 [65] 
Retrospective 11 non responders 
20 poor responders 
treated with CC (low 
dosage) + IVF  
All the patients were 
previously treated with 
hMG +GnRH agonist 
n= 11 received CC  
n=20 received  CC 
CPR per oocyte collections 
Non-responders, (9.1%)  
Poor responders (10%)  
CPR in previous long agonist 
protocol 11.9%. 
No significant difference 
There is no 
significant 
benefit/advantage of 
using long protocol 
in poor responders. 
 
The numbers were 
too small to 
generate a sound 
opinion. 
       
Branigan et al.2000 
[29]  
Prospective 
Cohort 
32 women with tubal or 
pelvic adhesive disease, 
normal ovulating cycles, 
under the age of 40. 
Received CC 100mg from 
cycle day3, for 8 days. 
Two months ovarian 
hypothalamic 
suppression with OC 
(Desongen) for LH 
suppression. 
No LH surges occurred. 
Mean mature oocytes 
retrieved:  3.2 
90% fertilisation rates 
Mean embryos transferred: 
2.5 
CPR: 32.8% (21/64) per 
retrieval 
Protocol is a low 
cost and low risk 
alternative to 
conventional IVF 
with comparable 
PRs. 
The use of OCP for 
LH suppression is a 
cheap acceptable 
strategy in IVF  
       
LH=Luteinizing hormone, ET=Embryo transfer, E2=Oestradiol, TDS=three times a day, NC=Natural cycle, CC=Clomiphene Citrate, CPR=Clinical pregnancy 
rate, VEGF=Vascular endothelial growth factor, FF=Follicular fluid, OCP=Oral contraceptive pill, hMG= human menopausal gonadotropin 
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Study Design Study Intervention  Outcomes Conclusion Comment 
Tokuyama et al. 
2002 [31] 
Prospective 
Comparative 
study 
38 patients undergoing 
IVF-ET, divided into 3 
groups: determine VEGF 
in FF 
Group 1: hMG (n=19) 
Group 2: CC (n=10) 
Group 3: natural cycles 
(n=9)  
hMG cycle and 
CC treatment 
Group 1 show lower VEGF 
in FF than group 2 or 3. 
Group 1 had higher number 
of oocytes harvested. 
However the results were 
not significant. 
VEGF concentration 
in FF correlates with 
number of follicles 
irrespective of the 
ovulation induction 
protocol. 
Role of endocrine 
markers in IVF still 
needs to be 
emphasised in 
selected patients 
Their role cannot 
be recommended 
routinely  
       
Ragni et al. 2012 
[28] 
RCT non-
inferiority trial 
304 women with 
compromised ovarian 
reserve based on day 3 
FSH>12IU/ml on two 
occasions, or previous 
poor response (< 3 
oocytes) to hyper 
stimulation  
n=148 to CC  
n=156 to short GnRHa 
protocol with high doses 
of gonadotropins  
CC 150mg day 
3-7 
The delivery rate per 
started cycle were: 
CC:  n=5/148 (3%)  
GnRH a: n = 7/156 (5%) 
P=0.77 
No significant difference 
No side effects were 
observed. 
 
In women with 
compromised 
ovarian reserve, 
ovarian stimulation 
with CC or high 
dose gonadotropins 
led to similar 
pregnancy chance 
but CC is less 
expensive. 
Premature 
cessation of the 
study reduced the 
sample size and 
affected the power 
negatively.    
LH=Luteinizing hormone, ET=Embryo transfer, E2=Oestradiol, TDS=three times a day, NC=Natural cycle, CC=Clomiphene Citrate, CPR=Clinical pregnancy 
rate, VEGF=Vascular endothelial growth factor, FF=Follicular fluid, OC=Oral contraceptive, hMG= human menopausal gonadotropin 
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Table 2, Part B: Clomiphene in combination with gonadotropins with/without GnRH antagonists 
Study Design Study Intervention Outcomes Conclusion Comment 
Williams et al. 2002 
[14] 
Retrospective 
case-
controlled 
study 
55 patients underwent IVF 
using CC 100mg day 3-7 
then 150IU of 
Gonadotropin from cycle 
day 9 until day of hCG. 
Embryo transfer on day 3 
after retrieval. Compared 
to 55 patients undergoing 
standard GnRHa long 
protocol and ET on day 3. 
CC + 
Gonadotropin 
stimulation in 
normal 
responders. 
No antagonists. 
Less medication (5.7 ± 
4.2 v/s 25.0 ± 7.5 
ampoules, P<0.5) 
Less mature oocytes (4.8 
± 2.6 v/s 16.2 ± 7.5, 
P<0.5) 
Fewer ET (2.9 ± 1.1 v/s 
3.5 ± 0.9 P<0.5) 
CPR were equivalent in 
both groups; (16/43, 37% 
vs. 21/51, 41%) [P=0.85] 
OPR also similar; 13/43, 
30% v/s 17/51, 33% 
P=0.92 
16% cycles cancellation 
due to poor follicular 
growth in CC v/s 7% in 
GnRHa. Cost of 
medication: 45% less in 
CC/Gonadotropin group. 
 
Equivalent 
CPR/OPR 
45% reduction in 
cost to patient 
 risk of cycle 
cancellations 
Little 
cryopreservation 
 
A simple and cheap 
alternative. 
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone,  recLH & rLH=recombinant 
luteinizing hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram  
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Study Design Study Intervention  Outcomes Conclusion Comment 
Weigert et al. 2002 
[43] 
Prospective 
randomised 
study 
294 infertile women 
undergoing IVF-ET  
154 cycles stimulated with 
CC + rec FSH + rec LH 
and 140 cycles with long 
GnRHa + rec FSH. 
CC:100mg CD1 - 
5 
rec FSH: rec LH 
3:1 (225:75IU) 
every alternative 
day. 
Prednisone 
7.5mg × 1 month. 
All patients pre-
treated with COC 
for 18-26 days. 
No antagonists. 
Pregnancy rate per ET 
42.9% in CC group vs. 
36.6% in long GnRHa 
protocol. No significant 
difference 
Cancellation rate were 
similar (16.9% vs. 15.7%) 
[p=0.3] 
OHSS higher in long 
GnRHa protocol group 
(10% vs. 3% in CC group) 
[p=0.02] Significant 
Comparable 
pregnancy outcome 
Less gonadotropin 
used. 
Significantly 
reduced risk of 
OHSS in the non 
agonist group.  
Good outcomes. 
       
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone,  recLH & rLH=recombinant 
luteinizing hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram  
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Study Design Study Intervention  Outcomes Conclusion Comment 
Tavaniotou et al. 
2002 [15] 
Retrospective 
analysis 
40 patients enrolled 
Group I: 20 patient 
stimulated with CC + 
Gonadotropin + Cetrorelix 
0.25mg 
Group II: 20 patients 
stimulated with 
Gonadotropin + 0.25mg 
Cetrorelix Evaluating LH 
in follicular + luteal phase 
during IVF cycle. 
CC 100mg/d, 
CD2-6 
HMG or rFSH 
from day 4 
Cetrorelix 0.25mg 
from day 7. 
 
LH levels were 
significantly higher during 
follicular + luteal phases 
in CC stimulated cycles. 
(5.2 ± 4.2 IU vs. 1.8 ± 1.4 
IU in non CC group, 
P<0.001) 
LH concentrations 
are significantly 
higher in the 
follicular + luteal 
phase of CC 
stimulated cycles 
despite antagonist 
administration. 
Simply managing a 
dose adjustment is 
necessary to 
suppress LH surge. 
Data very 
heterogeneous 
using CC with rFSH 
or HMG  
Although the study 
expressed higher 
levels of LH in 
follicular + luteal 
phase, no comment 
on clinical 
pregnancy rates.  
       
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone,  recLH & rLH=recombinant 
luteinizing hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram  
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Study Design Study Intervention  Outcomes Conclusion Comment 
Engel et al. 2002 
[16] 
Prospective 
non-
randomized 
trial 
Evaluate the possibility of 
using CC in combination 
with gonadotropin in 
antagonist protocol. 
Specially to evaluate the 
equivalence of rFSH and 
HMG with regards to the 
rate of HCG 
administration. 107 
patients  
HMG group n=54, rFSH 
group n=53 between June 
1997 and Oct 1999. 
Protocol I: CC 
100mg from 
CD2/3 for 7 days 
rFSH or HMG 
from CD 6 
(225IU) 
Cetrorelix 0.25mg 
from CD6 until 
day of HCG 
All ICSI cycles 
Protocol II: CC 
100mg x 5/7 only 
Protocol III: CC 
100mg x 5/7 plus 
FSH or HMG on 
CD 6 (150IU) 
Protocol IV: CC 
100mg x 5/7 plus 
FSH or HMG from 
CD 3 (150IU) 
Slightly more oocytes but 
not significant difference 
with HMG (7.2 ± 5.31 vs. 
5.5 ± 3.75) 
Similar number embryos 
obtained in both HMG 
and rFSH group (3.64 ± 
2.43 vs. 3.38 vs 1.87) 
CPR were comparable; 
(25.9% HMG vs. 13.8% 
rFSH) 
Overall LH Surge rate 
was 21.5%  
Protocol I -  27.3% 
Protocol II -  25% 
Protocol III – 11% 
Protocol IV -27.5 % 
The rate was always 
higher in rFSH group 
(26.4% rFSH vs. 16.7% 
HMG) explaining slightly 
reduced PR. 
Increase risk of 
premature LH 
Suggesting caution 
in the use of CC 
soft stimulation 
protocols. 
No significant 
difference in CPR 
Inconsistency in the 
protocol 
 
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone,  recLH & rLH=recombinant 
luteinizing hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram  
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Study Design Study Intervention  Outcomes Conclusion Comment 
Mansour et al.2003 
[55]  
Comparative 
study 
189 couples, first ICSI 
treatment. 
Group 1 (n=33): CC 
150mg/d CD 2-6 HMG 
150 IU, days 6-10 
Cetrorelix 0.25mg/d when 
leading follicle is  > 16mm 
in the absence of LH 
surge. 
Group II (n=156): 0.1 mg 
Decapeptyl a day + HMG 
CC + HMG + 
Cetrorelix 
 
CPR: 8/33 (24%) in CC 
group vs. 92/156 ( 59%) 
in long protocol (P=0.019) 
Statistically significant 
Cost of medication: 1110 
± 492 EP in CC vs. 1928 
± 456 in long protocol. 
Total cost per pregnancy: 
19653 EP in CC vs. 
10047 EP in GnRHa. 
CC+ HMG + 
antagonist protocol 
is not cost effective 
and should not be 
recommended. 
Very small 
numbers in CC 
group 
       
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone,  recLH & rLH=recombinant 
luteinizing hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram  
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Study Design Study Intervention  Outcomes Conclusion Comment 
Hwang JL et al. 
2003 [56] 
Observational 
study 
40 women undergoing 
ICSI for male infertility. 
CC 100mg from day 3-7 + 
HMG 150 IU days 4, 6, 8 
and from day 9 adjusted 
according to follicular 
response. 
Cetrorelix 2.5mg given 
once follicle of 14mm is 
present 
If no hCG given after 4 
days of Cetrorelix then 
0.25mg were given daily 
until day of HCG. 
Evaluate the efficacy to 
suppress premature LH 
surge  
CC + HMG + 
Cetrorelix initial 
high dosage 
(2.5mg) plus 
added small 
dosage (0.25mg) 
if necessary 
4/40 (10%) needed 
additional 0.25mg 
Cetrorelix. 
Single dose 2.5mg 
Cetrorelix effectively 
suppressed the LH surge 
for 4 days in all patients. 
Premature LH surge did 
not occur in any patients. 
The CPR & OPR were 
16/40(40%) and 14/40 
(35%) respectively. 
LH was 
successfully 
prevented by 
Cetrorelix 2.5mg 
once off dosage. 
Single high dosage 
of Cetrorelix 
appears to be 
effective for LH 
suppression versus 
multiple small 
dosages 
 
       
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone,  recLH & rLH=recombinant 
luteinizing hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram  
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Study Design Study Intervention  Outcomes Conclusion Comment 
Tavaniotou et al. 
2003 [62]  
Prospective 
trial 
46 patients enrolled 
Group 1: 18 sequentially 
stimulated CC + 
gonadotropin + Cetrorelix 
0.25mg. 
Group II: 28 Simultaneous 
stimulation with CC + 
gonadotropin + Cetrorelix 
0.25mg 
Evaluate for premature 
LH surge and its impact 
on pregnancy outcomes. 
Sequential CC + 
gonadotropin + 
Cetrorelix versus 
Simultaneous CC 
+ gonadotropin + 
Cetrorelix 
  
Cycle cancellation rates: 
22% in sequential 
protocol vs. 7% in 
simultaneous group 
(significant difference) 
CPR per ET: 
18.1% in sequential group 
vs. 29.1% in simultaneous 
group. (not significant) 
Premature LH surge was 
11.1% in sequential vs. 
28.5% in simultaneous 
group. 
Pregnancy rates were 
12.5% with LH surge vs. 
29.6% in patient without 
LH surge. 
Sequential 
CC/HMG is not 
recommended for 
CC/HMG/antagonist 
cycles. 
Cetrorelix 0.25mg 
was associated with 
high LH surge. 
Premature LH 
surges were 
associated with 
adverse treatment 
outcome. 
Type of CC/HMG 
regimen seems to 
be important for 
prevention of 
premature LH 
surge. Trials will be 
needed to evaluate 
this effect in a non-
antagonist protocol.  
 
       
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone,  recLH & rLH=recombinant 
luteinizing hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram  
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Study Design Study Intervention  Outcomes Conclusion Comment 
Engel et al. 2003 
[54] 
Prospective 
randomized 
feasibility 
study 
10 patients enrolled. 
n=5: CC + HMG + 
Cetrorelix 3mg single 
dose. 
n=5: CC + rFSH + 
Cetrorelix 3mg single 
dose. Evaluate the 
efficiency to suppress LH. 
CC + HMG + 
Cetrorelix and 
CC + FSH + 
Cetrorelix. 
 
No premature LH surge 
(LH > 10IU/ml) or 
(progesterone > 1ng/ml) 
occurred. 
Overall take home baby 
rate of 30%. 
No significant difference 
in the outcomes.  
Single dose 
Cetrorelix 3mg is 
effective in 
preventing 
premature LH 
surge. 
Study involved 
small numbers 
       
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone,  recLH & rLH=recombinant 
luteinizing hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram  
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Study Design Study Intervention  Outcomes Conclusion Comment 
Fiedler et al. 2003 
[60] 
Retrospective 
data analysis 
1354 patients treated with 
CC + gonadotropin + 
antagonist between Jan 
1998  Dec. 2001.  
CC: 100mg CD 5-9, HMG 
or rFSH 150 IU from day 
9 until day of HCG. 
Cetrorelix 0.25mg daily 
from day 10 until day of 
HCG. 
4704 patients treated with 
long GnRH agonist 
protocol.  
No routine measurement 
of LH. 
CC + HMG or 
rFSH + 
antagonist versus 
Long GnRH 
agonist protocol. 
LBR per cycle: 21.3% 
GnRHa vs. 19.5% CC 
CPR per cycle: 
1594/4704 (33.9%) long 
protocol vs. 
424/1354 (31,3%) CC 
Miscarriage rate: 21.6% 
long protocol vs. 22.9% 
CC protocol. 
No significant difference 
between two groups 
 
CC + gonadotropins 
+ antagonists is an 
ideal protocol in 
selected group of 
patients 
Comparable 
outcomes in both 
regimens 
P values not 
recorded 
       
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone,  recLH & rLH=recombinant 
luteinizing hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram  
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Study Design Study Intervention  Outcomes Conclusion Comment 
Lin YH et al. 2007 
[64] 
Prospective 
observational 
study 
50 patients who had 
excessive ovarian 
response required 
coasting but failed to 
conceive. 
CC: 100mg CD 3-7 
HMG: 2-3 ampoules on 
day 4,6,8 then daily from 
day 9 
Cetrorelix 2.5mg when 
leading follicle >14mm. If 
no HCG after 4 days, 0.25 
mg was added daily until 
day of HCG. 
Evaluate the incidence of 
OHSS, E2 and need for 
coasting 
CC + HMG + 
Cetrorelix 
treatment versus 
Long protocol 
GnRHa  
 
Coasting 50/50 (100%) 
vs. 4/50 (8%) P<0.05  
No premature LH surge  
in CC HMG group 
Cycles cancelled: 8/50 
(22%) GnRH vs. 1/50 
(2%) CC [P<0.05] 
OHSS: 9/50 (18%) GnRH 
vs. 1/50 (2%) CC [P<0.05] 
Severe OHSS: 1/9 (2%) 
v/s 0% (NS) 
CPR per fresh ET per 
cycle: 3/50 (6%) v/s 21/50 
(42%) P<0.05(significant) 
Significant higher 
cancellation rates & 
OHSS rates with GnRH 
CC + HMG + 
Antagonist ideal 
alternative for 
patients with 
previous hyper 
response. 
Ideal protocol to 
prevent OHSS 
       
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone,  recLH & rLH=recombinant 
luteinizing hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram  
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Study Design Study Intervention  Outcomes Conclusion Comment 
Lin YH et al. 2007 
[63] 
Prospective 
observational 
study 
113 couples with male 
factor infertility 
undergoing ICSI. 
106 cycles analysed. 
CC 100mg CD 3-7 + 
HMG day 4, 6, 8, then 
daily from day 9. 
Cetrorelix 2.5mg once off 
when the leading follicle is 
≥ 14mm. 
Evaluate oestradiol 
patterns throughout the 
cycles. 
CC + HMG + 
Cetrorelix 
 
Serum oestradiol rose in 
48 cycles (45,3%) after 
Cetrorelix administration. 
It plateaued in 26 cycles 
(24.5%) + dropped in 32 
cycles (30.2%) 
CRP: 37.5% in E2 rise vs. 
42.3% E2 plateau vs.  
37.5% in E2 drop.No 
significant difference. No 
correlation between LH 
and E2 levels. All patients 
had ET. 
Oestradiol patterns 
after Cetrorelix 
injection show no 
correlation with 
clinical outcome + 
ovarian reserve. 
Falling oestradiol is 
not associated with 
adverse outcome 
Similar pregnancy 
rates were 
observed. 
The role of 
oestradiol in IVF 
cycle continued to 
be questioned and 
defined.  
       
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone,  recLH & rLH=recombinant 
luteinizing hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram  
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Study Design Study Intervention  Outcomes Conclusion Comment 
Yanaihara et al. 
2008 [58] 
Retrospective 
analysis 
308 IVF cycles for IVF via 
mild ovarian stimulation: 
CC 100mg day 3-7,  
rFSH daily from day 5 
daily/or HMG in repeat 
every other day. 
Cetrorelix daily 0.25mg 
when dominant follicle  > 
14mm 
LH evaluated at the time 
of antagonist and at the 
time of HCG injection 
CC + rFSH + 
Cetrorelix 
 
50/308 (16%) LH level 
dropped less than one-
third and the control LH 
level were within 1/3. 
CPR: 18% in the LH 
levels < 1/3 vs 39% in the 
control group. 
IPR: 18% in the LH levels 
< 1/3 vs 26% in the 
control group. 
LH levels below 1/3 
at the time of HCG, 
is associated with 
significantly lower 
IPR and CPR. 
 
Caution for severe 
LH suppression 
with high dose 
Cetrorelix 
       
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone,  recLH & rLH=recombinant 
luteinizing hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram  
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Study Design Study Intervention  Outcomes Conclusion Comment 
Noorashikin et al. 
2008 [48] 
Prospective  
non 
randomized  
controlled 
study 
95 first cycles ICSI 
patients. 
n=54: low dose 
CC 100-150mg CD2-6 
rFSH 75-150 IU  
No Antagonists 
n=41 Standard dose 
gonadotropin + antagonist 
protocol 
rFSH 225-450IU from 
CD2  
Cetrorelix 0.25mg/d when 
leading follicle is 13 mm 
until HCG trigger 
CC + low dose 
rFSH only 
No antagonists 
versus 
Standard dose 
rFSH + 
Antagonist 
protocol. 
Fewer oocytes in LS vs 
standard  (P<0.0005) 
Fewer embryos in LS vs 
standard  (P<0.0005) 
CPR per transfer: 43,2%  
LS vs 50% Standard (not 
significant) 
More freezing cycles in 
standard than in LS 
(P<0.001) 
 
Comparable CPR 
Less medication in 
LS 
Lower cost in LS 
Acceptable CPR 
without antagonists’ 
administration. 
No comment on LH 
surge in the non-
antagonist group. 
       
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone,  recLH & rLH=recombinant 
luteinizing hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram  
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Study Design Study Intervention  Outcomes Conclusion Comment 
Karimzadeh et al. 
2010 [23] 
Prospective 
RCT  
243 enrolled between Jan 
2008-Dec 2008 but only 
200 were analysed per 
group. 
Group B: CC 100 CD 3-7  
rFSH 75IU daily from CD5  
GnRH antagonist 
Cetrorelix 0.25mg/d when 
dominant follicle is  
≥12mm 
Added HMG 75IU to rFSH 
(= 150 IU) from day 8 
Group A : Buserelin 
from previous menstrual 
cycle day 21 day (long 
protocol) + 
rFSH 150-225IU daily. 
Main outcome was OPR. 
Group B: CC + 
gonadotropin + 
antagonists 
versus  
Group A: 
Buserelin long 
agonist protocol. 
 
Significantly higher. 
Number of  oocytes in  
Group A vs Group B (9± 
2.2 vs 5.42± 1.5, P=0.00) 
 
No reported cases of  
OHSS in CC group [ 
6(6%) v/s 0, p=0.02] 
4 cycles (4%) cancelled in 
CC group v/s none in 
Buserelin group. 
Significantly  more 
gonadotropin used in 
Group A vs Group B (22 ± 
3.6 v/s 12.1 ± 4.3, 
P=0.00) 
OPR per transfer: 26.5% 
in Group A vs 33.3% in 
Group B (NS)  
No difference in 
endometrial thickness 
(P=0.41) 
CC + gonadotropin 
+antagonist 
protocol is as 
effective as 
conventional 
protocols. 
No comment on LH 
surge in the CC 
group 
Noted cancellation 
rates in CC but 
comparable and 
favourable 
outcomes.  
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone,  recLH & rLH=recombinant 
luteinizing hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram, NS= Not significant  
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Study Design Study Intervention  Outcomes Conclusion Comment 
Aleyamma et al. 
2011 [49] 
Retrospective 
analysis 
143 women evaluated: 
CC: 50 mg daily from 
CD2 until the day of HCG. 
Intermittent  HMG 150IU 
from CD5 on alternative 
days  
Cycles monitored by USS 
only. 
CC + HMG 
protocol. 
No antagonists 
104/143 underwent ET 
(73%) and  27% cycles 
cancellation rate 
LBR per cycle = 14% 
(20/143) 
LBR per transfer = 19% 
No cases of OHSS 
 
Authors felt that the 
LBR were 
acceptable at a 
reasonable cost. 
It is an option for 
patient who cannot 
afford conventional 
IVF.  
At least LH 
monitoring should 
be considered in 
minimal stimulation 
using CC.  
       
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone,  recLH & rLH=recombinant 
luteinizing hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram  
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Study Design Study Intervention  Outcomes Conclusion Comment 
Jovanovic et al. 
2011 [26] 
Retrospective 
study 
4859 poor responders 
enrolled between 2005-
2009 but 125 cycles 
involving 48patients were 
analysed. 
Group 1: Gonadotropin  
450 – 600 IU 
+ CC 100mg CD 2-6 
+ Cetrorelix 0.25mg when 
leading follicle ≥ 13mm. 
Group II: 
Gonadotropin 450-600IU 
+ Cetrorelix 0.25mg as 
above 
29 patients involving 85 
cycles were also 
analysed. 
Group I: CC + 
gonadotropins as above 
Group II: Letrozole 5mg 
CD 2-6 + gonadotropins 
A: CC + high 
dose 
gonadotropin  
versus 
High dose 
gonadotropin 
alone. 
 
B: CC + 
gonadotropin 
versus Letrozole 
(LZ) + 
gonadotropin 
A: CPR: 2/55(4%) in Non-
CC vs 5/60(8%) CC group 
(Not significant) 
Less cancellation cycles 
in CC group (p<0.05) 
Significant 
 
 
B: CPR: 0% CC vs 2/45 
(4%) LZ group 
Similar endometrial 
thickness (8.2±0.4mm vs. 
8.2±0.4mm) 
No significant difference 
in cycle cancellations 
 
CC as an adjunct to 
high dose 
gonadotropins in 
poor responders is 
beneficial.  
LZ group was 
associated with 
increased oocytes 
at retrieval but 
overall not superior 
to CC as an 
adjunct. 
Data is very 
heterogeneous and 
the numbers were 
small.  
       
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone,  recLH & rLH=recombinant 
luteinizing hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram  
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Study Design Study Intervention  Outcomes Conclusion Comment 
Gibreel et al. 2012 
[19] 
Systematic 
review  & 
meta-analysis 
2536 participants (14 
randomised studies) 
6 studies: CC + 
gonadotropin vs long 
gonadotropin GnRHa 
protocol. 
2 studies: CC + 
gonadotropin(Gn) vs short 
protocol GnRHa 
1 trial: 3 arm study: CC + 
Gn vs. GnRHa long vs. 
GnRHa short 
1 trial: CC + Gn + mid 
cycle antagonist (Ant) 
protocol  
4 trials: CC + Gn + mid 
cycle Ant vs. long GnRHa 
CC ± Gn ± mid 
cycle  antagonist 
versus 
Long and short 
agonist GnRHa 
protocol. 
Similar outcomes 
regarding  LBR or CPR in 
CC + Gn ± mid cycle  
antagonist vs. long or 
short GnRHa 
LBR (5 RCTs,  1079 
women; OR 0.93, CI 0.69 
– 1.24)  
CPR (11 RCTs, 1864 
women; OR 1.07, CI 0.85 
– 1.33) 
Significant reduction in 
OHSS: 
(5RCTs, 1559 women; 
OR 0.23, CI 0.10 – 0.52) 
 
No significant 
difference in 
outcomes in terms 
of LBR or CPR 
between CC + Gn + 
Ant vs long agonist 
protocol. 
Significant 
reduction of OHSS. 
 
Review included 
old studies 
 
No cost 
comparison in the 
analysis.  
Review included 
studies by Ashrafi 
[42], Fiedler [60], 
Karimzadeh [23] 
and Weigert [43]. 
       
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone,  recLH & rLH=recombinant 
luteinizing hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram  
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Study Design Study Intervention  Outcomes Conclusion Comment 
Figueiredo et al. 
2013 [24] 
Systematic 
review and 
meta-analysis 
CC + Gn + Ant vs. 
GnRHa protocol 
7 trials (702) participants 
CC + Gn + Ant vs 
long agonist 
protocol 
LBR: No significant 
difference between two 
protocols 
(55/182, 30.2%  CC vs. 
47/181. 26.0%, non-CC 
P=0.26) 
CPR : (98/346, 28.3% CC 
vs. 84/356, 23.6% non-
CC, P=0.12) 
No difference in other 
outcomes such as 
endometrial thickness and 
number of oocytes 
retrieved. Significant 
reduction in OHSS (0.5% 
vs. 4.1%, P=0.01) 
 
CC + Gn + Ant 
protocol is 
associated with 
reduced amount of 
medication and 
significant reduction 
in OHSS risk but no 
effect on LBR and 
CPR.  
Similar findings as 
the Cochrane 
review. 
The review 
included the 
following studies: 
Karimzadeh [23 ] 
and 
Karimzadeh [59 ]  
       
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone,  recLH & rLH=recombinant 
luteinizing hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram  
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Study Design Study Intervention  Outcomes Conclusion Comment 
Ashrafi et al. 2005 
[42] 
Randomised 
prospective 
trial   
154 Poor responders 
enrolled between June 
2003 – July 2004 
Group 1: n=45, HMG 150 
IU from CD3 Group 2: 
n=52, GnRHa long 
protocol + HMG 225 IU/d 
Group 3: n=34 100mg CC 
CD3-7 + HMG 150IU from 
CD6 
Evaluate LH surge, 
number of oocytes, and 
cancellation rates. 
CC + Gn 
No antagonists 
LH was higher in all 
groups except in the long 
GnRHa protocol (30.5% 
in HMG vs. 28% in CC vs. 
0% GnRHa,   P=0.004) 
Significant 
Similar cancellation rate 
(P=0.537) NS 
More ampoules used in 
GnRHa (P=0.0001) 
Significant 
Similar cancellation 
rates and mainly 
due to poor 
follicular response 
and premature LH 
surge. 
 
Risk of premature 
LH surge noted in 
both CC and HMG 
cycles. 
       
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone,  recLH & rLH=recombinant 
luteinizing hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram, NS= Not significant  
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Study Design Study Intervention  Outcomes Conclusion Comment 
Karimzadeh et al. 
2011 [59] 
Randomised 
controlled trial 
159 poor responders 
enrolled between March 
2008 – May 2010 (women 
≥ 38yrs, previous IVF with 
≤ 3 oocytes retrieved after 
conventional stimulation ± 
E2 ≤ 500pg/ml on the day 
of HCG) 
All received COC x 21 
days   
Group 1: n=79,  
CC, CD 3-7. 
rFSH/HMG 225 IU from 
day 5 daily. 
Daily Ganirelix 0.25 mg 
daily from leading follicle 
of ≥14mm 
Group II: n=80, Buserelin 
56/mcg  twice daily from 
cycle day 2, rFSH/HMG 
for 225-300 IU/d from 
CD2 
CC + Gn + Ant 
versus Buserelin 
+ Gn protocol 
More gonadotropin in 
microflare protocol 
(P=0.000) 
More days of stimulation 
in microflare  (P =  0.003) 
Endometrial thickness 
higher in mild / CC 
protocol (P = 0.001) 
More oocytes + mature 
oocytes in microflare 
protocol (P=0.005) 
Similar cycle cancellation 
in both groups. 
CPR/cycle: 24.10% vs. 
16.20%, slightly higher in 
CC group but NS. 
CPR/transfer 31.10% vs. 
21%, NS. 
Reassuring CPR 
with mild CC 
protocol  
Fewer days of 
stimulation in CC 
protocol. 
Less stressful to 
patients. 
 
GnRHa appears 
not to be effective 
and ideal for poor 
responders. 
 
CC= Clomiphene Citrate, IU= International Units, ET= embryo transfer, COC= combined oral contraceptive, CPR= clinical pregnancy rate, OPR= ongoing 
pregnancy rate, LBR = live birth rate, CD= menstrual cycle day, recFSH & rFSH= recombinant follicle stimulating hormone, recLH & rLH=recombinant luteinizing 
hormone, RCT= randomized controlled trial, EP= European pound, mcg= microgram, NS= Not significant 
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DISCUSSION 
 
The ongoing need to simplify ART, particularly controlled ovarian stimulation, should 
remain the fundamental purpose and goal for all involved with the care of infertile 
couples. It is simply to make it patient friendly, less stressful and to reduce the cost of 
medication. However, this must be guarded against pregnancy outcomes. 
 
Currently the long GnRH agonist protocol is still regarded as the gold standard 
regimen for ovarian stimulation in ART [1]. However, the GnRH antagonist protocols 
are slowly becoming the routine in most units. Both of these protocols are generally 
expensive, using large amounts of gonadotropins [24].  
 
This therefore emphasises the need to continue to explore the mild ovarian stimulation 
protocols in ART. CC protocols should be appraised and carefully be used on an 
individual basis.    
 
Clomiphene Citrate alone  
 
We have reviewed a total of seven studies that reported the outcomes of ART in CC 
only IVF/ICSI cycles (Table 1, Part A). There were two RCTs in which one study by 
McDougall et al. [27] compared CC cycle and NC IVF outcomes. The author reported 
significantly higher CPR in CC (18%) vs NC (0%) [27]. Another trial by Ragni et al. [28] 
evaluated 304 women with compromised ovarian reserve. Participants were allocated 
to receive CC only (n=148) or short GnRH agonist treatment with high doses of 
gonadotropins (n=156). The delivery rates per started cycle were comparable, CC 
(3%) vs GnRHa (5%) pvalue = 0.77 [28]. However the CC regimen was much cheaper 
than the agonist protocol.  Three prospective studies by Branigan et al. [29], Gentry et 
al. [30] and Tokuyama et al. [31] reported reassuring results. CPR of 32.8% was 
observed in a study by Branigan et al. involving 32 women with normal ovulatory cycles 
treated with CC alone following two months of ovarian hypothalamic suppression with 
OCP [29]. Gentry et al. further showed comparable and acceptable CPR at different 
endometrila thickness measurents, (20%) : >4mm <7mm, (32%): > 7mm< 10mm and 
(28%) in >10mm in women treated with CC only [30]. The final outcome of ART 
treatment is to achieve a successful pregnancy and a singleton live birth [32]. In the 
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early days of IVF, the outcomes were reported to be generally poor due to a 
combination of factors [33]. In an attempt to improve pregnancy outcomes, quality 
assurance in the laboratory has improved, skills development and training of scientists 
and clinicians has also improved and ovarian stimulation protocols have changed and 
continue to be modified on individual bases. Higher numbers of embryos were also 
transferred as a strategy to increase pregnancy rates, at the risk of multiple 
pregnancies with subsequent financial burden on individual patients and the health 
system as a whole [34,35]. The suggestion of mild ovarian stimulation together with 
single embryo transfer to lower the complication risks of IVF/ICSI treatment became 
widely accepted in countries in which IVF is government subsidised [34,36]. 
 
Mild ovarian stimulation protocol is defined as ovarian stimulation using oral agents 
alone or in combination with gonadotropins with or without mid-cycle GnRH 
antagonist, with the aim of retrieving ≤7 oocytes per cycle [4]. Clinical pregnancy rates 
in IVF cycles of normal responders using CC alone could vary from 16% per started 
cycle to 34% per embryo transfer. [29, 30, 37, 38]. 
 
In studies that reported low pregnancy rates, endometrial thickness of (<7mm) and 
failure to support the luteal phase were postulated reasons for the poor outcomes. 
There are also reports of pregnancy rates over 30% with endometrial thickness of 
>7mm, adequate suppression of premature LH surge and luteal phase support 
independently influencing the outcomes [29, 30, 37]. In comparison with natural cycle 
IVF, the CC alone stimulated cycle had >90% chance of oocyte retrieval and embryo 
transfer [29, 38]. But again, the risk of premature LH surge in CC stimulated cycles 
associated with poor oocyte quality and as a result high pregnancy wastage remains 
a concern [39].  
 
In women with poor ovarian response or compromised ovarian reserve, the use of CC 
alone in IVF has been associated with pregnancy rates of 5-10% [28, 40]. Although 
the rates were low, they were comparable to those of women treated with conventional 
long GnRH agonist protocol and large amounts of gonadotropins [40]. Therefore, CC 
alone IVF may be considered an option in older women with depleted ovarian reserve. 
It also appears to be better than natural cycle IVF. It is interesting to note that the anti-
oestrogenic adverse effects of CC were not reported as the major concern in these 
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studies. More so, CC alone IVF could present another option in very limited resource 
settings. 
 
The limitations of the studies we reviewed are that most trials were old, sample sizes 
were small and the data was heterogeneous with different outcomes. Future studies 
should evaluate the role of aromatase inhibitors such as Letrozole [41] in IVF with 
regard to pregnancy rates, premature LH surge and endometrial thickness. 
 
Clomiphene Citrate plus gonadotropins without gonadotropin releasing 
hormone antagonists 
 
We have reviewed a total of five studies that reported the outcomes of ART in CC plus 
gonadotropins without GnRH antagonist IVF/ICSI cycles (Table 2, Part B). There were 
two RCT’s, one by Ashrafi et al [ 42 ] that evaluated 154 women with poor ovarian 
response, group 1 (n= 45, HMG only), group 2 (n= 52, GnRHa long protocol + HMG) 
and group 3 (n=34, CC + HMG). The results showed significantly higher LH surge in 
HMG group (30.5%) vs CC/HMG (28%) vs GnRHa (0%) pvalue=0.004. Significantly 
more ampoules of gonadotropins were required in the GnRHa group (pvalue=0.0001) 
[42]. However, the authors reported similar cancellation rates in all groups HMG 
(38.8%) vs GnRHa (50.1%) vs CC/HMG (45.5%) p=0.537 [42]. Similar findings of 
significantly high cancellation rates were reported by Gibreel et al. in a systematic 
review and meta-analysis [19]. Another trial by Weigert et al. [43] randomised 154 
infertile women to receive CC + recFSH + recLH and 140 infertile women to receive 
long protocol GnRHa + recFSH. Pregnancy rates per ET were reported as 42.9% in 
the CC group vs 36.6% in the GnRHa group and not significant [43]. The cancellation 
rates were similar in both groups, 16.9% CC vs 15.7% GnRHa and also not significant 
[43]. However the risk of OHSS was significantly higher in the GnRHa group (10%) vs 
CC group (3%) pvalue=0.02 [43].  
 
Gonadotropin preparations have been commercially available since the 1960s and 
since 1978 following the birth of the first IVF baby they have been used increasingly 
in ART such as IVF or ICSI [44]. Gonadotropins may be used alone or in combination 
with oral agents. The aim of adding oral agents such as CC to gonadotropins is to 
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increase the number of oocytes for fertilization and to use less expensive 
gonadotropins.  
 
A retrospective study by Williams et al. [14] reported comparable clinical pregnancy 
rates per transfer of (37% vs 41% pvalue=0.85) in minimal stimulation vs long GnRHa 
protocol respectively. In a sub-analysis of data comparing GnRH antagonist, Ganirelix 
(n=10) vs non Ganirelix group (n=10), there was no statistically significant difference 
in the number of oocytes retrieved (4.9  3.1 vs 3.1  1.0) and the number of embryos 
transferred (2.5  1.1 vs 2.8  1.1) [14]. There were no reported cases of premature 
LH surge in this study and the cost of medication was 45% less in the CC and 
gonadotropin group [14]. 
 
Seqawa et al. in a study of 3654 infertile women showed equal CPR of 34.1% in CC 
+ 150 IU of hMG versus 34.2% in CC + 75IU of hMG on alternate days [45]. Another 
retrospective analysis of over 19000 IVF cycles from a single unit reported impressive 
pregnancy rates of 43.6% using CC 50mg for five days plus 50IU hMG from cycle day 
8 [46]. In a pilot study by Garzo et al., embryo quality was found to be significantly 
better in a low stimulation protocol [47]. Noorashikin et al. in a prospective non-
randomized trial comparing (n=54) CC + delayed rFSH without antagonist versus 
conventional rFSH + GnRH antagonist, Cetrorelix (n=41) found no statistically 
significant difference in CPR between two groups (43.2% in CC vs. 50% in antagonist 
group) [48]. There were more freezing cycles in the antagonist group (P < 0.001) but 
the total treatment cost was also higher in the antagonist group (USD 13 200 LS vs. 
USD 24 900 antagonist) [48]. 
The reported high rates of cycle cancellation [42] [43] [49] are the main reason behind 
the notion and promotion of short mid-cycle introduction of GnRH antagonists in 
IVF/ICSI treatment.  
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Clomiphene Citrate plus Gonadotropins with mid-cycle gonadotropin releasing 
hormone antagonists  
 
We have reviewed a total of 15 studies that reported the outcomes of ART in CC plus 
gonadotropins with mid-cycle GnRH antagonist IVF/ICSI cycles (Table 2, Part B). The 
findings of two systematic reviews and meta-analysis by Gibreel et al. [19] and 
Figueiredo et al. [24] were similar. Gibreel et al. [19] analysed all RCT’s that compared 
CC, alone or in combination with gonadotropins, with conventional gonadotropin cycle 
(GnRH agonist or antagonist). Fourteen RCTs involving 2536 participants showed 
comparable outcomes between two regimens. LBR from 5 RCTs, n=1079 participants 
did not show any statistical difference (OR 0.93, CI 0.69-1.24) [19]. Other outcome 
measures such as OPR and CPR did not show any statistical defference either [19]. 
In five studies (n=1559 participants) there was a statistically significant decrease in 
the incidence of OHSS in CC protocol (OR 0.23, CI 0.10-0.52) [19]. In a second review 
by Figueiredo et al, [24], seven RCT’s (n=702 participants) that compared CC + 
gonadotropins + GnRH antagonists with gonadotropins + GnRH agonists or 
antagonists were analysed. LBR were reported by two studies and no significant 
difference was observed (RR 1.16; CI 0.84-1.62) [24]. CPR from all seven studies did 
not show any significant difference either (RR 1.22, CI 0.95-1.56) [24]. There was 
significant reduction in the risk of OHSS in the CC group with Peto OR 0.20, CI 0.06-
0.69 [24].  
The GnRH antagonist was originally developed as a non-steroid contraceptive drug 
[50] but eventually became useful and beneficial in assisted reproduction. Mid-cycle 
use of GnRH antagonist in ART results in immediate suppression of pituitary 
gonadotrophins for a period of 8 hours with rapid recovery of normal secretion of 
endogenous LH and FSH [50, 51].  The use of a GnRH antagonist in a standard IVF 
when compared with a GnRH agonist protocol have shown no significant difference in 
probability of live birth and ongoing pregnancy rates [17, 19, 52, 53]. There was 
significantly lower incidence of OHSS in the GnRH antagonist group (P < 0.00001) 
[53]. 
 
Mid-cycle administration of a GnRH antagonist in mild ovarian stimulation has been 
associated with conflicting results, with some authors reporting unacceptably high 
levels of premature LH surge (LH>10IU) before HCG trigger [15,16]. In both studies, 
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the dosage of the GnRH antagonist used was a fixed regimen of 0.25mg daily from 
cycle day 6 or 7. A follow-up randomised feasibility study by Engel et al., using a higher 
single dose of GnRH antagonist, Cetrorelix 3mg, reported no cases of premature LH 
surge with a take home baby rate of 30% [54] – therefore concluding that a single dose 
of 3mg is effective in the prevention of premature LH surge.    
 
Mansour et al. reported that a CC + hMG + mid-cycle antagonist protocol is not cost 
effective and should not be recommended [55]. However, more studies further 
reported effective suppression of premature LH surge with a 2.5mg single dose of 
Cetrorelix, adding 0.25mg daily only if no HCG is given after 4 days since the initial 
Cetrorelix administration [56, 57]. Yanaihara et al., however, cautioned that severe 
drop in LH levels below a third (1/3) of the baseline may result lower pregnancy rates 
(18%) in low LH <1/3 versus (39%) in the control [58]. 
 
Subsequent trials reported a comparable clinical pregnancy rate with no significant 
difference between a CC/hMG/antagonists protocol and a long GnRH agonist protocol 
[23, 57]. Similar findings were also reported by Karimzadeh et al. in a study of poor 
responders, with CPR per started cycle of (24% in CC vs 16% in Buserelin) [59]. More 
studies reported LBR of 19.5% in CC vs 21.3% GnRHa and 36% in CC vs 35% in 
GnRHa [57, 60]. 
 
The antagonist protocol is still relatively unaffordable, particularly in a limited resources 
setting, therefore simpler and cheaper methods to lower the risk of premature LH 
surge amongst other adverse events of CC still need to be explored.  Kawachiya et 
al., in a study of 543 cycles using CC 50mg from cycle day 3 until the day of HCG or 
GnRH agonist trigger, reported lower rates of premature LH surge (5%), therefore 
suggesting that CC was sufficiently effective in suppressing LH surge in the minimal 
stimulation IVF protocol [61]. In another study, Branigan et al. also reported no cases 
of premature LH surge with two months’ pre-treatment of an oral contraceptive pill prior 
to stimulation with CC 100mg from cycle day 3 for 8 days [29]. 
 
Tavaniotou et al. proposed the simultaneous use of CC and gonadotropins as opposed 
to the sequential protocol (begin stimulation with CC and add gonadotropins later in 
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the cycle) since the former was associated with lower risks of premature LH surge (7% 
versus 22%) [62]. 
 
 
CONCLUSION 
 
The current available evidence suggests CC + gonadotropin + mid-cycle antagonist 
protocol as an effective protocol with comparable live birth rates and ongoing 
pregnancy rates versus long GnRH agonists protocol. In addition, it is associated with 
reduced risk of OHSS and a lesser number of gonadotropins required. CC + 
gonadotropins without antagonists also appear to be a feasible protocol in well 
selected groups of patients, young and normal endocrine profile. The risk of premature 
LH surge may be minimised by pre-treatment with an oral contraceptive pill or 
prolonged use of CC during stimulation or simultaneous use of CC and gonadotropins. 
However, all these strategies still need to be evaluated rigorously in large trials. The 
future of CC alone in IVF is rather doubtful, especially in the era of gonadotropins with 
or without GnRH antagonist protocols.  Perhaps in a selected group of patients, young 
women with normal endocrine profile and women with compromised ovarian reserve 
or previous poor response to conventional stimulation, the CC alone protocol may 
present an alternative  with fair results and at a low cost.  
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CHAPTER 3: A SIMPLE METHOD OF EXTENDED 8-DAY COURSE OF 
CLOMIPHENE CITRATE VERSUS 5-DAY COURSE IN AN ATTEMPT TO 
SUPPRESS PREMATURE LUTEINIZING HORMONE SURGE IN AN ASSISTED 
REPRODUCTIVE TECHNOLOGY PROGRAMME: A RANDOMIZED CONTROLLED 
TRIAL 
 
SYNOPSIS 
 
Objective: To determine whether the use of a prolonged eight-day course of CC 
versus the standard use of five days is an effective method to prevent premature LH 
surge in an ART programme.  
 
Design: Prospective randomised controlled study. 
 
Setting: Tygerberg Academic Hospital, Reproductive Medicine Unit. 
 
Population: Couples attending fertility clinic for IVF/ICSI treatment for female and 
male infertility problems. 
 
Methods: Eligible participants were randomised into one of two treatment groups 
using a simple randomization schedule assigned via numbered sealed envelope 
following patient assessment. In Group A, the patients were stimulated with CC 100mg 
for 5 days from cycle day 3 to 7 plus hMG 150-225IU that was added on cycle days 4, 
6, 8 and/or 10. In Group B patients were stimulated with CC 100mg for 8 days from 
cycle day 3 – 10 plus hMG that was added on cycle days 4, 6, 8 and/or 10. Cycles 
were monitored with ultrasound and urinary LH tests. No endocrine blood tests were 
performed. hCG was administered when there was a dominant follicle of ≥18mm, 
followed by oocyte retrieval 34-36hrs later.The luteal phase was supported with 
vaginal progesterone.  
 
Main outcome measures: The rates of premature LH surge, cycle cancellation rates, 
live birth and clinical pregnancy rates.  
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Results: Two hundred and thirty eight (238) patients were enrolled and randomized 
and a total of 227 were analysed. The percentage risk of premature LH surge was 
similar in both groups with (20% Group A vs 24% Group B, P=0.6) and there was no 
significant difference in live birth and clinical pregnancy rates per initiated cycle 
between the two groups, 6.4% Group A vs 10.6% in Group B and 12% (A) vs 17% (B) 
respectively. Cycle cancellation rates were also similar between the two groups, 36% 
(A) vs 31% (B).   
 
Conclusion: The trial shows that a prolonged 8-day course of CC does not suppress 
premature LH surge in an ART programme. 
 
Keywords: Clomiphene Citrate, premature LH surge, IVF, ART, pregnancy outcomes 
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BACKGROUND 
 
Oral CC is the first choice treatment for unexplained infertility and ovarian dysfunction 
with anovulatory cycles [1,2]. The choice is simply motivated by its effectiveness in 
inducing ovulation (ovulation rates of 70 – 80%) [3]. Added advantages include oral 
administration, known safety profile and being inexpensive [1]. However CC is 
reported to be associated with detrimental anti-oestrogenic effects on the 
endometrium and the cervical mucus [4]. Added to this negative concern is the 
increased risk of premature LH surge associated with CC usage. The incidence of 
premature LH surge is reported to be as high as 30% (15-30%) [5-8]. This may lead 
to impaired oocyte quality, lower pregnancy rates and increased miscarriages rates 
[9-12]. 
 
Trounson et al. reported a live birth rate per transfer of 8/23 (17%) with the use of CC 
alone in IVF [13]. Subsequently other authors have also reported positive outcomes 
of CC alone in IVF such as a high chance of oocyte retrieval (81%) [14] and a clinical 
pregnancy rate of 32.8% (21/64) per retrieval [15]. 
 
With the widespread increase in the usage of gonadotropins in the late 1980s and 
early 1990s, CC was used as an adjunct together with gonadotropins, with intent to 
increase the number of oocytes at the time of retrieval but keeping the number of 
gonadotropins low, thereby reducing the cost of treatment. The sequential or 
combined use of CC and gonadotropin protocols was reported to be associated with 
good clinical pregnancy rates, as high as 40% [16-18]. But the reported high 
cancellation rates of approximately 17% remain a concern [16]. In addition, the fewer 
oocytes retrieved per cycle and fewer embryos available for transfer as a result of 
these regimes have motivated the introduction of hypothalamo-pituitary suppression 
protocols with GnRHa, which eliminated the premature LH surge and led to multi-
follicular recruitment and development [19]. However, this agonist protocol requires 
excessive amounts of gonadotropins, the treatment duration is long and exhausting 
and it results oestrogenic deprivation (hot flushes, vaginal dryness, headache) with 
overall stress for individual patients [5]. As an alternative to mitigate the above-
mentioned effects of long GnRHa protocols, the mid-cycle GnRH antagonists were 
introduced in IVF, providing immediate suppression of pituitary gonadotropin for a 
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certain period of time [20]. It is important to note that the use of GnRH antagonists 
when compared with GnRHa in terms of probability of LBR and OPR, there were no 
significant differences between the two protocols [21,22]. 
 
In limited resource settings the described pituitary suppression protocols remain 
expensive and therefore make treatment unaffordable, further encouraging clinicians 
to explore other strategies to prevent premature LH surge and high cancellation rates 
in CC and gonadotropin ART cycles. Previously described methods to reduce the risk 
of premature LH surge includes prolonged use of CC until the day of hCG trigger [23], 
simultaneous administration of gonadotropins and oral progesterone beginning on 
menstrual cycle day 3 during ovarian hyperstimulation for IVF [24-26], pre-treatment 
with OCP prior to stimulation with CC [15] and/or simultaneous use of CC and a 
gonadotropin protocol [7]. The limitation of these strategies is that they lack robustness 
with evidence gathered from retrospective data or studies. 
 
We therefore conducted a prospective RCT, comparing traditional use of CC of 5 days 
starting from cycle day 3 to 7 with prolonged use of CC for 8 days starting from cycle 
day 3 to 10 in a sequential gonadotropin cycle without mid-cycle GnRH antagonist. 
 
Materials and Methods 
 
Study design and setting 
This study is a prospective RCT performed at Tygerberg Academic Hospital, 
Reproductive Medicine Unit, between June 2011 and December 2014, involving 349 
patients who were candidates for ART in the form of IVF or ICSI. The study was 
approved by the ethics committee of Stellenbosch University, Faculty of Medicine and 
Health Sciences with reference no N11/08/256.  We included female patients aged 
between 18 and 40 years of age. It had to be their first IVF treatment with regular 
menstrual cycles and a BMI (kg/m2) of 18-30. All causes of infertility were included. 
Patients with previously failed IVF treatment, presence of large ovarian cyst >3cm on 
ultrasound, congenital uterine anomalies, severe endometriosis, BMI >35 and 
ovulatory dysfunction were excluded from the study. All participating patients signed 
a written consent form. 
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Treatment protocols 
The patients were randomised into one of two treatment groups using a simple 
randomization schedule assigned via numbered sealed envelopes following patient 
assessment. 
 
In group A, the patients were stimulated with CC (Fertomid, Cipla MEDPRO RSA) 
100mg for 5 days from cycle day 3 to 7. hMG (Menopur, FERRING, SA) 150-225IU 
was added on cycle day 4, 6, 8 and/or 10. 
  
In group B patients were stimulated with CC (Fertomid, Cipla MEDPRO RSA) 100mg 
for 8 days from cycle day 3 to 10. hMG (Menopur, FERRING SA) was added on cycle 
day 4, 6, 8 and/or 10. No baseline endocrine biochemical testing was performed in 
either group. Ultrasound was performed in both groups on cycle day 3 for AFC and 
evaluation for any cyst formation. The subsequent ultrasound was performed on cycle 
day 8 or 9 and thereafter according to follicular growth. LH was assessed from cycle 
day 9 and if negative, performed on alternative days until the day of hCG 
administration (Ovitrelle 250µg/0.5ml, Merck SA). If LH positive, the oocyte retrieval 
would be performed within the next 24 hours. hCG (Ovitrelle, Merck SA) 250µg/0.5ml 
was administered when there was a leading follicle of >18mm. 
 
Endometrial thickness was measured on the days of follicular assessment and the day 
of hCG administration. No serum oestradiol (E2) levels were performed in either group. 
Oocyte retrieval was performed 34-36 hours after hCG administration by ultrasound-
guided puncture of follicles, and IVF or ICSI was performed. All the embryos were 
assessed and scored morphologically before transfer [27].  
 
ET was performed on day 2, 3 or 5 under ultrasound guidance with a Sage ET 
catheter. Luteal support with vaginal progesterone (Utrogestan, Medi Challenge SA) 
400mg daily was started on the day of embryo transfer until the day of quantitative 
pregnancy test. Cycles were cancelled if no follicular growth occurred, no dominant 
follicles were present and with poor embryo growth. 
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Implantation was confirmed by measuring serum -hCG levels on days 10 and 12 after 
ET. CPR is defined as the ultrasound presence of foetal cardiac activity at 7 weeks of 
gestation and OPR as the presence of foetal cardiac activity at >12 weeks of gestation. 
LBR is also defined as the birth of a singleton, live baby at term.  
 
Primary outcome measure was the rate of premature LH surge between two groups, 
and secondary outcome measures were CPR, LBR, cancellation rates and 
miscarriage rates. 
 
Data and statistical analysis 
Results are presented as the median and the range unless otherwise indicated. 
Comparison of outcome measures was performed using a t test for symmetrical 
continuous data and the Mann-Whitney test for non-symmetrical continuous data. The 
X2 test was used for binary variables. The trial comparing two treatment regimens was 
designed to detect a difference of at least 20% (power 80%) in LH surge between the 
5 days and 8 days of CC administration. Two hundred and twenty eight patients should 
be included to achieve this aim. P-value<0.05 was considered the limit of statistical 
significance. Data was analysed using STATA 13 Software. 
 
Results 
There were no significant differences between the groups with regard to demographic 
characteristics such as age and indication for treatment (Table 1). Two hundred and 
thirty eight (238) patients were enrolled and randomized. In the 5-day protocol of CC, 
5 patients were excluded and we lost follow-up in 1 patient. In the 8-day protocol of 
CC, 5 patients were excluded but we did NOT lose any patients to follow-up. Therefore 
we analysed 124 patients in the 5-day CC group vs 103 patients in the 8-day CC group 
(Figure 1). 
 
There was no significant difference in the number of oocytes and number of 
metaphase II in the two groups. [2(0-12) vs 3(0-15), P=0.16] and [2(0-11) vs 3(0-14), 
P=0.15] (Table 2). 
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However, there was a significantly higher fertilization rate in the long 8-day protocol vs 
the short 5-day protocol [1(0-10) vs 2(0-13), P = 0.04]. The number of good quality 
embryos was similar in both groups (1.5 ± 1.0 vs 1.8 ± 0.9; CI 95% 1.51–1.8). The 
percentage risk of premature LH surge was also similar in both groups. (20% vs 24%, 
P=0.6) and there was no significant difference in clinical pregnancy rates between the 
two groups. (12% vs 16%, P=0.3) No cases of OHSS were reported during the study 
period. 
 
Conventional IVF and ICSI were used in the same percentage of cycles in both groups 
(Table 2). 
  
There were similar high cycle cancellation rates in Group A and Group B, due mainly 
to poor embryo development and no embryos available for transfer. There was no 
difference in the endometrial thickness between the two groups and the number of 
gonadotropins used in both groups was also similar. 
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Figure 1: Recruitment, randomisation, follow-up and drop-outs over the period 
of the study  
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Table 1: Demographic characteristics of patients undergoing an IVF/ICSI 
treatment in Clomiphene Citrate protocol, randomised for two different regimes.  
 
Variables 5 days group A 
(n = 124) 
8 days Group B   P-value 
(n = 103) 
Age (years)a 35.5 ± 4.9 35.3 ± 4.3              0.37 
BMI (kg/m2)a  28.3 ± 2.6 28.1 ± 2.1              0.26 
Infertility causes 
• Tubal factor 
•  Teratozoospermia 
 
56 (45%) 
31 (25%) 
 
42 (40.7%)            0.2 
26 (25.2%)            0.5 
BMI = Body mass index, aMean ± SD 
Statistically significant values (P < 0.05) 
No significant difference between two groups. 
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Table 2: Clinical outcomes of the two different treatment groups 
 
MII = Metaphase II, LH = Luteinizing hormone, HCG = human chorionic gonadotropin, OHSS ovarian hyperstimulation syndrome  
a = median values reported, b = statistically significant value (pvalue =0.04), c = data presented as the mean ± SD, mm = milliemeter 
 
Variables 5 Days, Group A 
(n = 124) 
8 Days, Group B 
(n = 103) 
Between group differences 5% 
(Confidence limit) 
P Value 
Number of oocytesa retrieved 2 (0 – 12) 3 (0 – 15)  0.16 
Number of MII oocytesa 2 (0 – 11) 3 ( 0 – 14)  0.15 
Number of oocytes fertilized (Fertilization rate)a 1 (0 – 10) 2 ( 0 – 13)  0.04 b 
Number of embryos transferreda 1 (0 – 4) 2 (0 – 4)  0.06 
Endometrial thickness (mm)c 
Day of embryo transferc 
8.6 ±1.3 
2.9 ± 0.9 
8.5±1.2 
3.0 ± 0.8 
  (CI 95%: -0.2 – 0.4) 
  (CI 95% : 2.8 – 3.1) 
0.27 
0.8 
Good quality embryos available for transferc 1.5 ± 1.0 
CI 95% (12 – 1.7) 
1.8 ± 0.9 
CI 95% (1.6 – 2.10) 
  (CI 95%  1.51 – 1.8) 0.9 
Premature LH Surge (Positive urinary LH before 
HCG administration 
25 (20%) 25 (24%)  0.6 
Clinical pregnancy rate per started cycle 15 (12%) 17 (16.5%)  0.3 
Clinical pregnancy rate per embryo transfer 15 (19.4%) 17 (24%)  0.5 
Live birth rate per cycle 8 (6.4%) 11 (10.6%)  0.2 
Live birth rate per embryo transfer 8 (7.8%) 11 (15.5%)  0.3 
Miscarriage rate 7 (46.6%) 6 (35%)  0.9 
Cycle cancellation rate 45 (36%) 32 (31%)  0.4 
OHSS 0 (0%) 0 (0%)   
ICSI 51 (41%) 44 (42.7%)  0.68 
IVF 73 (58.8%) 56 (54%)  0.66 
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DISCUSSION 
  
The introduction of GnRH agonist and GnRH antagonist in IVF/ICSI cycles was to 
eliminate the risk of premature LH surge which was reported to be approximately 20-
25% in CC and/or gonadotropin cycles [6, 28]. However these protocols require 
significantly large amount of gonadotropins at a very high cost [29]. In the present 
randomised trial, we recorded an early LH surge (positive urinary LH prior hCG 
administration) as high as 20% in the five-day course of CC (group A) vs 24% in the 
eight-day course of CC (group B).The findings are similar to those reported in other 
studies [5, 28]. The fundamental issues of concern with premature LH surge include 
high cycle cancellation rates, unplanned oocyte retrieval, poor timing for oocyte 
maturation, resulting in aged oocytes and a detrimental effect on the endometrium 
preparation for implantation with overall lower pregnancy rates [4,5,12]. 
 
Amongst the less expensive proposed methods to prevent premature LH surge 
[7,15,23-26]. Kawachiya et al. in a retrospective study of 543 cycles, using 50mg CC 
from cycle day 3 and 75IU hMG every other day from cycle day 8 until the leading 
follicle developed to 18mm in diameter and administration of CC stopped at the time 
of oocyte maturation trigger with 300 microgram (g) GnRH agonist (Buserelin), 
reported low rates of premature LH levels (5%) [23]. The conclusion of the study was 
that prolonged usage of CC is sufficiently effective to suppress the premature LH surge 
in minimal stimulation IVF protocol. On the contrary, in the current trial the rate of 
premature LH surge in a prolonged CC arm was as high as 24%. 
 
In the current trial, LH testing was performed once daily from cycle day 9 up to the day 
of hCG administration using the collected urine sample. The aim was to reduce the 
costs related to serum blood testing. Several studies have reported high sensitivity 
rates ranging from 85% to 100% of urine LH tests to predict ovulation in advance [30]. 
It has since been recognized as an acceptable method used by patients to assess LH 
peaks in order to time intercourse and also by physicians during trials and/or treatment 
cycles for infertility [31-34].  
 
Stellenbosch University  https://scholar.sun.ac.za
75 
 
The high cycle cancellation rates of 36% and 31% in Groups A and B of this study 
respectively were largely due to cancelled embryo transfers as a result of poor embryo 
development and growth. Cycle cancellation for poor follicular growth was 10% (Group 
A) and 11% (Group B). The selective and strict transfer of good quality embryos could 
explain the overall high cycle cancellation rates and low miscarriage rates (Table 2) in 
this study. The miscarriage rate in CC treatment is reported to range from 13 to 25% 
[12]. All these negative outcomes are attributed to premature LH surge. In both Group 
A and B, the oocyte retrieval was achieved in 90% and 89% respectively, with no 
significant difference in the number of oocytes retrieved (P=0.16) and the available 
number of metaphase II oocytes (P=0.15). Therefore we did not cancel the cycle 
simply because of an early LH surge, and acceptable rates of oocyte retrieval were 
observed. This practical approach has also been described in the literature [35]. 
 
Although there was a significantly higher number of fertilized oocytes in Group B [1 (0-
10) vs 2(0-13), P=0.04], the available number of good quality embryos for transfer was 
not significantly different in both Group A and B. [1.5 ± 1.0 vs 1.8 ± 0.9, CI 95% 1.51 
– 1.8). The clinical pregnancy rates per started cycle of (12% vs 16.5%, P = 0.3) and 
the LBR per transfer of (7.8% vs 15.5%, P=0.3) were lower when compared to pituitary 
suppressed protocols results. Similar pregnancy outcomes have previously been 
reported in CC treatment cycles [7,13]. These low pregnancy outcomes could be 
explained by high levels of early LH surge in this study. Furthermore, it is important to 
note that despite a high oocyte retrieval rate and satisfactory fertilization rate, the high 
cancellation rate due to poor embryo development might be a reflection of the impact 
of high LH on the oocyte quality [5]. There was no difference in the endometrial 
thickness in both groups, with the average thickness of 8.5 ± 1.2mm at the time of 
hCG administration. Previous studies have also reported no detrimental effect on the 
endometrial growth and morphology in CC and/or gonadotropins ART treatments 
[36,37]. And no cases of OHSS were reported in this study. 
 
Financial and geographic limitations are profound barriers to the use of ART and 
favour CC treatment amongst low socio-economic status and rural women [2]. This 
phenomenon is shown in the increased usage of CC in women between 30-44 years 
of age, indicating a growing demand for fertility treatments in this population [2]. The 
use of aromatase inhibitors such as Letrozole as a substitute or an alternative to CC 
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is still debatable because of similar ovulation rates with no significant benefit observed 
other than associated high costs of the drug [38]. The fact remains, in low resource 
settings, GnRH agonist and/or GnRH antagonist can never be easily affordable. 
Therefore the use of CC in conjunction with gonadotropins will remain an alternative, 
if not the first line of treatment. The ongoing research and effort should strive towards 
achieving acceptable pregnancy rates in these protocols as shown by Williams et al. 
and Weigert et al. [16,39]. Furthermore, affordable strategies to lower the risk of 
premature LH surge should continue to be evaluated in robust clinical trials. To our 
knowledge, this study is the first randomised controlled trial to evaluate the role of 
prolonged CC usage as a strategy to prevent premature LH surge in IVF/ISCI cycles.  
 
In conclusion, this trial shows that prolonged usage of CC from cycle day 3 to cycle 
day 10 did not suppress the premature LH surge in a mild ovarian stimulation protocol 
using CC and gonadotropins IVF/ICSI treatment. Therefore other methods such as 
oral contraceptive pre-treatment and simultaneous progesterone administration 
should also be evaluated in larger and robust trials. 
 
  
Stellenbosch University  https://scholar.sun.ac.za
77 
 
REFERENCES 
 
1. Casper RF, Mitwally MFM. Review: Aromatase inhibitors for ovulation induction. 
J Clin Endocrinol Metab 2006; 91: 760-771. DOI:10.1210/jc.2005-1923 
2. Lisonkova S, Joseph KS. Temporal trends in clomiphene citrate: a population 
based study.Fertil Steril 2012; 97:639-44. DOI: 10.1016/j.fertnstert.2011.12.034 
3. Homburg R. Clomiphene citrate - end of an era? a mini – review. Hum Reprod 
2005; 20: 2043-2051. DOI: 10.1093/humrep/dei042 
4. Tarlatzis BC, Grimbizis G. Future use of clomiphene in ovarian stimulation, will 
clomiphene persist in the 21st century? Hum Reprod 1998; 13(9): 2356-2365.  
5. Zarek SM, Muasher SJ. Mild/minimal stimulation for in vitro fertilization: an old 
idea that needs to be revisited. Fertil Steril 2011; 95: 2449-55. DOI: 10. 
1016/j.fertnstert.2011.04.041 
6.  Engel JB, Ludwig M, Felberbaum R, Albano C, Devroey P, Diedrich K. Use of 
cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable 
approach to ‘friendly IVF’? Hum Reprod 2002; 17(8): 2022-2026 
7. Tavaniotou A, Albano C, Van Steirteghem A, Devroey P. The impact of LH serum 
concentration on the clinical outcome of IVF cycles in patients receiving two 
regimens of clomiphene citrate/gonadotropin/0.25mg cetrorelix. Reprod Biomed 
Online 2003; 6: 421-6 
8. Ashrafi M, Ashtiani SK, Zafarani F, Samani RO, Eshrati B. Evaluation of ovulation 
induction protocols for poor responders undergoing assisted reproduction 
techniques. Saudi Med J 2005; 26(4): 593-596 
9. Tarlatzis BC. Oocyte collection and quality. Assist Reprod Rev 1992; 2: 16-22 
10. Out HJ, Coelingh Bennink. Clomiphene citrate or gonadotrophins for induction of 
ovulation?  Hum Reprod 1998; 13: 2358-2369 
11. Saunders DM, Lancaster PA, Pedisich EL. Increased pregnancy failure rates 
after clomiphene following assisted reproductive technology. Hum Reprod 1992; 
7(8): 1154-8 
12. Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of 
ovulation. Hum Reprod Update 1997; 3: 359-365 
13. Trounson OA, Leeton JF, Wood C, Webb J, Wood J. Pregnancies in humans by 
fertilization in vitro and embryo transfer in the controlled ovulatory cycle. Science 
1981; 212: 681-2 
Stellenbosch University  https://scholar.sun.ac.za
78 
 
14. Ingerslev HJ, Højgaard A, Hindkjaer J, Kesmodel U. A randomized study 
comparing IVF in the unstimulated cycle with IVF following clomiphene citrate. 
Hum Reprod 2001; 16: 696-702 
15. Branigan EF, Estes MA. Minimal stimulation IVF using clomiphene citrate and 
oral contraceptive pill pretreatment for LH suppression. Fertil Steril 2000; 73: 
587-90 
16. Weigert M, Krischker U, Pöhl M, Poschalko G, Kindermann C, Feichtinger W. 
Comparison of stimulation with clomiphene citrate in combination with 
recombinant follicle-stimulating hormone and recombinant luteinizing hormone 
to stimulation with a gonadotropin-releasing hormone agonist protocol: a 
prospective, randomized study. Fertil Steril 2002; 78: 34-9 
17. Noorashikin M, Ong FB, Omar MH, Zainul-Rashid MR, Murad AZ, Shamsir A, 
Norsina MA, Nurshaireen  A, Sharifah-Teh NSMN, Fazilah AH. Affordable ART 
for the developing countries: a cost benefit comparison of low dose stimulation 
versus high dose GnRH antagonist protocol. J Assist Reprod Genet 2008; 25: 
297-303. DOI: 10. 1007/s10815-008-9239-9 
18. Okimura T, Kuwayama M, Kikuchi M, Segawa T, Takehara Y, Kato O. Large 
scale results for in vitro fertilization (IVF) using mild stimulation. Outcome from 
over 19000 cycles. Fertil Steril 2008; 90 (Suppl 1): A-18 
19. Maheshwari A, Gibreel A, Siristatidis CS, Bhattacharya S. Gonadotrophin-
releasing hormone agonist protocols for pituitary suppression in assisted 
reproduction. Cochrane Database Syst Rev 2011; 8: CD 006919. 
DOI:10.1002/14651858.CD006919.pub3 
20. Ditkoff EC, Cassidenti DL, Paulson RJ, Sauer MV, Paul WL, Rivier J, Yen SSC, 
Lobo RA. The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely 
blocks the luteinizing hormone surge but allows for resumption of folliculogenesis 
in normal women. Am J Obstet Gynecol 1991; 165: 1811-1817. 
DOI: http://dx.doi.org/10.1016/0002-9378(91)90037-R 
  
Stellenbosch University  https://scholar.sun.ac.za
79 
 
21. Al-Inany HG, Youssef M, Aboulghar M, Broeksman F, Sterrenburg M, Smit J, 
Abou-setta A. Gonadotropin-releasing hormone antagonists for assisted 
reproductive technology. Cochrane Database Syst Rev 2011; 11: CD001750. 
doi: 10.1002/14651858.CD001750.pub3 
22. Gibreel A, Maheshwari A, Bhattacharya S. Clomiphene citrate in combination 
with gonadotropins for controlled ovarian stimulation in women undergoing in 
vitro fertilization. Cochrane Database Syst Rev 2012; 11: CD008528. DOI: 
10.1002/14651858. CD008528.pub2 
23. Kawachiya S, Segawa T, Kato K,  Takehara Y, Teramoto S, Kato O. The 
effectiveness of clomiphene citrate in suppressing the LH surge in the minimal 
stimulation IVF protocol. Fertil Steril 2006; 86 (Suppl 2): P-751 
24. Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, Ai A, Shoham Z. 
Medroxyprogesterone acetate is an effective oral alternative for preventing 
premature luteinizing hormone surges in women undergoing controlled ovarian 
hyperstimulation for in vitro fertilization. Fertil Steril 2015; 104: 62-70. doi: 
10.1016/j.fertnstert.2015.03.022 
25. Zhu X, Zhang X, Fu Y. Utrogestan as an effective Oral Alternative for Preventing 
Premature Luteinizing Hormone Surges in Women Undergoing Controlled 
Ovarian Hyperstimulation for In Vitro Fertilization. Medicine 2015; 94: e909. doi: 
10.1097/MD.0000000000000909 
26. Escudero EL, Boerrigter PJ, Coelingh Bennink HJT, Epifanio R, Horcajadas JA, 
Olivennes F, Pellicer A, Simón C. Mifepristone Is an Effective Oral Alternative for 
the Prevention of Premature Luteinizing Hormone Surges and/or Premature 
Luteinization in Women Undergoing Controlled Ovarian Hyperstimulation for in 
Vitro Fertilization.  J Clin Endocrinol Metab 2005; 90: 2081-2088. doi: 
10.1210/jc.2004-1160 
27. Ebner T, Moser M, Sommergruber M, Tews G. Selection based on morphological 
assessment of oocytes and embryos at different stages of preimplantation 
development. a review. Hum Reprod Update 2003; 9: 251-262. DOI: 
10.1093/humupd/dmg021 
28. Hwang JL, Huang LW, Hsieh BC, Tsai YL, Huang SC, Chen CY, Hsieh ML, Chen 
PH, Lin YH. Ovarian stimulation by clomiphene citrate and hMG in combination 
with cetrorelix acetate for ICSI cycles. Hum Reprod 2003; 18: 45-49. 
DOI:10.1093/humrep/deg021 
Stellenbosch University  https://scholar.sun.ac.za
80 
 
29. Hovatta O, Cooke I. Cost-effective approaches to in vitro fertilization: Means to 
improve access. Int J Gynecol Obstet 2006; 94: 287-291. DOI: 10. 
1016/j.ijgo.2006.04.012  
30. Palmer OM, Grenache DG, Gronowski AM. The NACB Laboratory Medicine 
Practice Guidelines for Point -of-Care Reproductive Testing. Point of Care 2007; 
6: 265-272 
31. Odell WD, Ross GT, Rayford PL. Radioimmunoassay for Luteinizing Hormone 
in Human Plasma or Serum: Physiological Studies. J Clin Invest 1967; 46: 248-
255 
32. Behre HM, Kuhlage J, Gaßner C, Sonntag B, Schem C, Schneider HPG, 
Nieschlag E. Prediction of ovulation by urinary hormone measurements with the 
home use ClearPlan® Fertility Monitor: comparison with transvaginal ultrasound 
scans and serum hormone measurements. Hum Reprod 2000; 15: 2478-2482 
33. Antaki R, Dean NL, Lapensée L, Racicot MH, Ménard S, Kadoch IJ. An Algorithm 
Combining Ultrasound and Unrinary Luteinizing Hormone Testing: A Novel 
Approach for Intrauterine Insemination Timing. J Obstet Gynaecol Can 2011; 33: 
1248-1252 
34. Young SL, Opsahl MS, Fritz MA. Serum concentrations of enclomiphene and 
zuclomiphene across consecutive cycles of clomiphene citrate therapy in 
anovulatory infertile women. Fertil Steril 1999; 71: 639-44 
35. Fiedler K, Ludwig M. Use of clomiphene citrate in in vitro fertilization (IVF) and 
IVF/intracytoplasmic sperm injection cycles. Fertil Steril 2003; 80: 1521-1523. 
DOI: 10.1016/S0015-0282(03)02208-8 
36. Yanaihara A, Yorimitsu T, Motoyama H, Ohara M, Kawamura T. The decrease 
of serum luteinizing hormone level by a gonadotropin-releasing hormone 
antagonist following the mild IVF stimulation protocol for IVF and its clinical 
outcome. J Assist Reprod Genet 2008; 25: 115-8 
37. Karimzadeh MA, Ahmadi S, Oskouian H, Rahmani E. Comparison of mild 
stimulation and conventional stimulation in ART outcome. Arch Gynecol Obstet 
2010; 281:741-746. DOI: 10.1007/s00404-009-1252-4 
38. Kamath MS, George K. Letrozole or clomiphene citrate as first line for 
anovulatory infertility: a debate. Reprod Biol Endocrinol 2011; 9: 86. 
http://www.rbej.com/content/9/1/86.   
Stellenbosch University  https://scholar.sun.ac.za
81 
 
39. Williams SC, Gibbons WE, Muasher SJ, Oehninger S. Minimal ovarian 
hyperstimulation for in vitro fertilization using sequential clomiphene citrate and 
gonadotropin with or without the addition of a gonadotropin-releasing hormone 
antagonist. Fertil Steril 2002; 78(5): 1068-72 
  
Stellenbosch University  https://scholar.sun.ac.za
82 
 
CHAPTER 4: CHILDLESSNESS IN A LIMITED-RESOURCE COUNTRY; A 
PAINFUL SUFFERING TO ENDURE: PUBLIC-PRIVATE INTERACTION, A MODEL 
TOWARDS MAKING ASSISTED REPRODUCTION ACCESSIBLE 
 
SYNOPSIS 
 
Objective: To evaluate PPI as a strategy to make ART affordable 
 
Design: Prospective descriptive study 
 
Setting: Tygerberg Academic Hospital, Reproductive Medicine Unit 
 
Population: All women ages 20-45 years attending the fertility clinic for ART 
(IVF/ICSI) treatment for female and male infertility problems 
 
Methods: Clinical treatment records of all eligible participants were analysed. 
Treatment involved CC 100mg from cycle day 3 to 7 or day 3 to 10 in combination with 
alternate day administration of hMG 150-225IU from cycle day 4, 6 and 8. hCG was 
administered when the leading follicle of ≥18mm was present and the retrieval followed 
34-36hrs later. Cycle monitoring included the ultrasound and urinary LH testing with 
no use of any biochemical endocrine blood tests.  
  
Main outcome measures: LBR, CPR and also the direct costs of treatment to 
individual couple per cycle of ART.  
 
Results: Three hundred and seventy five (375) cycles of ART were performed and 
346 (92%) reached oocyte retrieval stage with a fertilization rate of 72.5%. The LBR 
per ET and per cycle started were 17.7% and 10.6% respectively, while the CPR per 
ET and per started cycle were 24% and 14% respectively. A cycle cancellation rate of 
40% was observed. A multiple pregnancy rate of 5.6% was recorded and there were 
no cases of OHSS. Direct costs of treatment per cycle were R7291 (563USD) (cycle 
costs R6000 – R8000). A cumulative pregnancy rate of 32% following three cycles of 
ART was also observed.  
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Conclusion: The study shows that PPI can be a possible and viable strategy to make 
ART affordable and accessible with reasonable pregnancy rates at low cost. The 
model can be implemented, reproduced and be sustained.  
 
Keywords: IVF, ICSI, ART, developing countries, limited resources, public private 
interventions 
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INTRODUCTION 
 
Infertility is undeniably a public and global health issue [1]. With over 5 million children 
being born following ART worldwide, this technique is still not widely available or used 
in either developing and developed countries because of its high costs [2]. The 
availability of funding or health insurance facilities for ART differs worldwide with 
optimal coverage in Belgium to absolutely no cover in the United States of America 
(USA) [3-5]. Cost is the major limiting factor and number one deterrent for infertile 
couples to seek ART treatment [6,7]. The cost drivers of IVF cycle in a relatively large 
private clinic are mainly medication (28%), clinicians’ fees and consultation (29%), and 
laboratory fees (35%) [8]. The first report on ART data monitoring in South Africa and 
sub-Saharan Africa (developing countries) shows that the ART needs of many couples 
are still unmet, with only 6% coverage [9]. This issue receives very little attention 
because most governments and authorities in the developing countries are faced with 
major health challenges such as high maternal morbidity and mortality, and infectious 
diseases including TB, HIV and malaria [10]. 
 
However the desire to have children especially in the developing countries presents 
much stronger negative psychosocial consequences from psychological distress, 
domestic violence, stigmatization and polygamy [11-13]. And couples will go to great 
length and difficulty to achieve this goal. Studies have shown that to have a healthy 
child, couples may accept a 20% risk of death and give up 29% of their income [14]. 
Chambers et al. further reported that one fresh cycle of IVF accounts for 52% of an 
individual’s average disposable income in states without ART insurance mandate [6]. 
There are more than 80 million couples affected by infertility worldwide and the 
majority of this population resides in the developing countries where funding for ART 
does not exist [15]. This protracted and painful undesired situation of childlessness for 
millions of couples in the developing countries has been well expressed by Murage et 
al. in a cross-sectional survey, showing that 26.1% of gynaecologic consultations in 
Kenya were related to subfertility and 50.3% were due to tubal factors, while 14.8% 
were due to male factors [16]. Simply, implying that more than 50% of fertility related 
problems were likely to require ART that is severely limited to only three private units 
at an exorbitant cost [16], thus expressing the dire demand for ART services in 
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developing countries. It has been shown that by reducing the cost of treatment and 
improving access to treatment is associated with improved patient safety and 
reduction in undesirable complications of high order multiple pregnancies [3, 17]. This 
situation is to be avoided at all possible costs in poorly resourced countries.  
 
The current paper seeks to evaluate and demonstrate PPI as a possible strategy to 
make ART accessible in the very limited resources settings by describing a series of 
patients managed through the model. 
 
PART A: The description of Public Private Interaction Model 
 
Public-private interaction is a model that involved negotiations and a signed level of 
agreement (SLA) between public sector hospital, Tygerberg Academic, and private 
clinic Drs Aevitas Institute of Reproductive Medicine, in Cape Town (Addendum A). 
 
Personnel 
 
Tygerberg Academic Hospital unit initially began functioning  only with the fertility 
specialist in charge of the programme (Dr Thabo Matsaseng) and two embryologists 
(Dr M Windt-de Beer and Mrs E Erasmus), who are full-time employees of 
Stellenbosch University and the Provincial Government of the Western Cape, 
respectively. The cycle bookings and arrangements were handled by the doctor in 
charge of the treatment, thereby eliminating clinic and administrative fees. The unit 
currently has an additional fertility specialist and a junior embryologist who were not 
part of the study. The newly recruited embryologist is the person now in charge of 
cycle’s co-ordination and bookings.  
 
Ovulation induction: Mild Ovarian Stimulation protocol (Figure 1) 
 
The patients were stimulated with CC (Fertomid, Cipla MEDPRO RSA) 100mg for 5 
days from menstrual cycle 3 to 7 and hMG (Menopur, FERRING, SA) 150-225 lU (2-
3 ampoules)  that was added on cycle day 4, 6, 8 and/or 10.  We generally do not use 
more than eight ampoules in total (1 ampoule =75IU). Ultrasound was performed on 
day 1-3 of the menstrual cycle before treatment was initiated. This was to evaluate the 
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AFC and to rule out ovarian cysts. Follicular monitoring began on cycle day 8 and was 
performed every alternate day until the day of hCG administration. Urine LH tests were 
performed from cycle day 9 and every alternate day and sometimes daily until the day 
of hCG administration. No endocrine biochemical tests were prepared as part of 
monitoring. In cases where spontaneous ovulation is highly suspected based on 
follicular size (>22mm) and weak positive urinary LH before hCG administration, 
NSAIDs Indomethacin (Arthrexin, Adcock Ingram SA) 25mg three times a day will be 
offered until the day of oocyte retrieval [18]. hCG (Ovitrelle, Merck SA) 250mcg/0.5ml 
was administrated where there was a leading follicle of >18mm. Oocyte retrieval was 
performed 34-36 hours after hCG administration by ultrasound guided puncture of 
follicles, and IVF or ICSI was performed.   
 
Laboratory – oocyte retrieval, insemination and embryo transfer 
  
Oocyte retrieval is done under conscious sedation without the need for anaesthesia, 
an anaesthetist or a theatre set-up. Patients receive Pethidine 100 mg intramuscularly 
15-30 minutes before the procedure and a 20ml local block with 1% Lignocaine without 
Adrenaline. They recover in a room near the laboratory for approximately 30 minutes 
after the procedure and are discharged in the company of a family member once they 
are fully awake. Sperm will be prepared on the day of oocyte retrieval using 3-layer 
density gradient centrifugation (90%–70%–40%) (PureSperm, Nidacon) followed by 
two washing steps in Earle’s Balanced Salt Solution + 5% Human Serum Albumin 
(HSA). Samples will be re-suspended in Global® (G-IVF, Life Global, USA) + 5% HSA 
and incubated at 36.5°C until fertilization. Oocyte-cumulus-complexes were placed in 
a 5ml tube with 1ml Global® for fertilization + 5% HSA (pre-equilibrated) and a volume 
equivalent to 50 000 to 100 000 motile sperm added. Fertilization and embryo culture 
will occur in a tissue culture incubator in an atmosphere of 5% CO2 in air, with 
confirmation of fertilization made 16-20 hours later. All embryos were assessed and 
scored morphologically before transfer [19]. ET was performed on day 2 or 3 under 
ultrasound guidance with a Sage ET catheter. Occasionally ET was performed on day 
5. Cryopreservation facilities are available when necessary. Consumables such as 
aspiration needles and embryo transfer catheters were provided by the private clinic 
following single use and therefore were properly sterilized before being re-used. This 
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was to further lower the cost of treatment without compromising patient safety and 
results. 
 
In summary, we were convinced that the model will assist in cutting costs at the level 
of medication, clinicians’ fees and laboratory fees, which are the biggest cost drivers 
in IVF treatment. The model was published in the local journal, SAJOG 2014; 20: 33-
34. Doi: 10.7196/SAJOG.814 and non-peer reviewed journal, Specialist Forum 2014. 
It also attracted a wide media interest with television broadcast on the BBC news 
channel (internationally) and eNCA news bulletin (national broadcaster). This has led 
to a request for the model to be evaluated for implementation by a local tertiary 
institution, Chris Hani Baragwanath hospital in Johannesburg via Dr Tshabalala. 
Through this model we describe the outcomes of patients managed by ART at 
Tygerberg Academic Hospital.  
 
PART B: A description of the first 375 cycles managed with ART through PPI 
model. 
 
Materials and Methods 
 
Design: Pragmatic, prospective descriptive study 
 
Setting: The ART treatment was provided by the Reproductive Medicine Unit at 
Tygerberg Academic Hospital (public)  
 
Data collection 
The study included all women who underwent ART in the form of IVF and ICSI in our 
unit from 2011 to 2014. It was couples who required ART irrespective of the diagnosis, 
age (limit ≤42 yrs of age), BMI (kg/m2) [limit <36]. There was no specific exclusion 
criterion for couples in their first cycle of ART. The patients were counselled on the 
treatment protocol, the cost of treatment and the success rates that are lower than 
those of conventional ART programmes. 
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Mild Ovarian Stimulation protocol (Figure 1) 
 
The patients were stimulated with CC (Fertomid, Cipla MEDPRO RSA) 100mg for 5 
days from menstrual cycle 3 to 7 and hMG (Menopur, FERRING, SA) 150-225 lU (2-
3 ampoules) that was added on cycle day 4, 6, 8 and/or 10.  We generally do not use 
more than eight ampoules in total (1 ampoule =75IU). Ultrasound was performed on 
day 1-3 of the menstrual cycle before treatment was initiated. This was to evaluate the 
AFC and to rule out ovarian cysts. Follicular monitoring began on cycle day 8 and was 
performed every alternate day until the day of hCG administration. Urine LH tests were 
performed from cycle day 9 and every alternate day and sometimes daily until the day 
of hCG administration. No endocrine biochemical tests were prepared as part of 
monitoring. In cases where spontaneous ovulation is highly suspected based on 
follicular size (>22mm) and weak positive urinary LH before hCG administration, 
NSAIDs Indomethacin (Arthrexin, Adcock Ingram SA) 25mg three times a day will be 
offered until the day of oocyte retrieval [18]. hCG (Ovitrelle, Merck SA) 250mcg/0.5ml 
was administrated where there was a leading follicle of >18mm. Oocyte retrieval was 
performed 34-36 hours after hCG administration by ultrasound guided puncture of 
follicles, and IVF or ICSI was performed.   
 
Laboratory – oocyte retrieval, insemination and embryo transfer 
 
Oocyte retrieval is done under conscious sedation without the need for anaesthesia, 
an anaesthetist or a theatre set-up. Patients receive Pethidine 100 mg intramuscularly 
15-30 minutes before procedure and a 20ml local block with 1% Lignocaine without 
Adrenaline. They recover in a room near the laboratory for approximately 30 minutes 
after the procedure and are discharged in the company of a family member once they 
are fully awake. Sperm will be prepared on the day of oocyte retrieval using 3-layer 
density gradient centrifugation (90%–70%–40%) (PureSperm, Nidacon) followed by 
two washing steps in Earle’s Balanced Salt Solution + 5% Human Serum Albumin 
(HSA). Samples will be re-suspended in Global® (G-IVF, Life Global, USA) + 5% HSA 
and incubated at 36.5°C until fertilization. Oocyte-cumulus-complexes were placed in 
a 5ml tube with 1ml Global® for fertilization + 5% HSA (pre-equilibrated) and a volume 
equivalent to 50 000 to 100 000 motile sperm added. Fertilization and embryo culture 
will occur in a tissue culture incubator in an atmosphere of 5% CO2 in air, with 
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confirmation of fertilization made 16-20 hours later. All embryos were assessed and 
scored morphologically before transfer [19]. ET was performed on day 2 or 3 under 
ultrasound guidance with a Sage ET catheter. Occasionally ET was performed on day 
5 . Cryopreservation facilities are available when necessary. Consumables such as 
aspiration needles and embryo transfer catheters were provided by the private clinic 
following single use and therefore properly sterilized before being re-used. This was 
to further lower the cost of treatment without compromising patient safety and results. 
 
Luteal support with vaginal progesterone (Utrogestan, Medi Challenge SA) 400mg 
daily was started on the day of ET and continued until the day of the quantitative 
pregnancy test. The cycle was cancelled if there was no follicular growth, no oocytes 
retrieved during aspiration, no fertilization and poor embryo growth. Implantation was 
confirmed by measuring serum ß-hCG levels on day 10 and 12 following ET (> 25lU 
on day 10 confirmed pregnancy). 
 
CPR is defined as the ultrasound presence of foetal cardiac activity at 7 weeks of 
gestation and OPR as the presence of foetal cardiac activity at >12 weeks of gestation. 
LBR is defined as the birth of a singleton, live baby at term. 
 
The primary outcome measure was to show whether public-private interaction can 
make ART affordable, looking at the cost of treatment cycle and the outcomes, in terms 
of live birth rate. 
 
Secondary outcomes include the number of oocytes retrieved, fertilization rates, 
clinical pregnancy rates, miscarriage rates and ectopic rates.  
 
The study was approved by the Health Research Ethics Committee of the Faculty of 
Medicine and Health Sciences (FMHS) of Stellenbosch University with reference no 
N11/08/256.  
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Data and Statistical analysis 
 
Data are presented as percentages (n) and means ± SD or range. 
 
The Kaplan-Meier survival estimates were used for prediction of pregnancy probability 
given the number of treatment cycles. 
 
The student t-test was used to compare the means and a p-value of <0.05 was 
considered to be statistically significant. All analyses were performed with Stata 13 
software. 
 
Results 
 
A total of 375 cycles were performed with this low cost model between 2011 and 2014. 
The average age of women was 34.9 ± 4.7 (oldest was 44 yrs) and the most common 
indications for treatment were tubal disorder (45.6%) and teratozoospermia (28.6%) 
[Table1]. A total of 346 cycles (92%) reached oocyte retrieval stage. The cycle 
cancellation rate in this study was 8%. At the time of aspiration no oocytes were 
obtained in 10.7% (37/346) of the cases despite the presence of the expected number 
of follicles, and in 16.7% of the cases there was no fertilization. In addition, 7.5% of 
the cases did not reach embryo transfer stage as a result of poor quality embryos 
(Table 2). We have observed that cycle cancellations as a result of poor follicular 
development and absence of oocytes at the time of aspiration (in the presence of 
follicles) occurred more frequently in patients with PCOS, previous cystectomy for 
endometrioma and advanced female age of >38yrs old.   
 
IVF and ICSI were performed in 202 (53.8%) and 167 (44.5%) cycles respectively. 
The mean number of oocytes retrieved was 4.3 ± 4.0 (0-20). There was fertilization 
failure in 58 (16.7%) cycles. There were significantly more failures with IVF, 38/58 
(65.5%) than ICSI, 20/58 (34.5%) p=0.0008. The mean number of embryos transferred 
was 2.99 ± 0.93 (range 1-4), with 77% (389/503) of good quality embryos available for 
transfer. A clinical pregnancy rate of 14.1% (53/375) per started cycle and 23.5% 
(53/225) per ET was achieved. Twelve clinical pregnancies ended in miscarriages 
22.6% (12/53) and 1 ended as an ectopic pregnancy (tubal) (1.9%). Therefore a total 
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of 40 babies were born, giving a LBR per stated cycle of 40/375 (10.6%) and LBR per 
ET of 40/225 (17.7%).  
 
A multiple pregnancy rate of 5.6% (3/53) was recorded and it was only twins, with no 
triplets observed. No cases of OHSS were recorded (Table 3). 
 
The probability of achieving a pregnancy following one, two and three cycles of IVF 
were 14.1%, 19.8% and 31.7% respectively (Table 4, Figure 2). There was no 
improvement in pregnancy chance between cycles 4 to 6 of treatment.  
 
The overall cost of IVF/ICSI cycle is R7 291.00 (563USD) which is direct cost to 
patient, and in the private clinics the cycle cost varies between R35 000 and R50 000 
(3 861 USD) (Table 5). 
 
Further cost comparison shows that infrastructure (rental fees), personnel salaries, 
medication and laboratory costs are the greatest cost drivers in IVF/ICSI treatments 
(Table 5).  
 
DISCUSSION  
 
There is an increasing demand, utilization and applications of ART worldwide owing 
to both the increasing effectiveness of treatment and the increasing rates of subfertility 
as couples delay childbirth [6]. The rising trend of utilization has been observed in the 
developed countries, particularly where there is public funding for ART [20]. However 
in the developing countries access to ART remains nothing but a dream to be realised 
[21], largely because of the high cost and unaffordability of treatment [6,7,16]. The 
strategies developed in an attempt to make ART affordable are not intended to 
compromise on quality, but at least to improve access to many who would otherwise 
be denied the opportunity and joy of parenthood [21, 22]. 
 
In this current study we present a PPI model in a limited resource setting.  According 
to the draft health charter, PPI is defined as one or more persons or entities involved 
in health care within the public sector interacting with one or more persons or entities 
involved in health care within the private sector or the non-governmental organization 
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sector with the intention to achieve mutual benefit. This includes public-private 
partnership (PPP) and PPI [23]. A PPP involves a contractual agreement between 
public and private parties in which the private party performs an institutional function 
or uses state assets and assumes substantial financial, technical and operational risk 
of the project in return for a benefit [23], and it requires participation, registration and 
approval of the National Treasury. However, any project that does not require any 
involvement of the National Treasury should be regarded as PPI [25], as illustrated in 
our model which is a contractual SLA signed between the hospital and the private 
sector. The relationship may be a once-off involvement or be on an ongoing basis. 
 
An optimally functioning laboratory is a prerequisite to ensure good results and the 
public hospital (Tygerberg Hospital) provided the infrastructure in which the clinic and 
the laboratory provided the platform for consultation, monitoring and performance of 
ART treatment. The hospital billed the patients according to their level of salary income 
for every visit to the clinic (Addendum A). In the private setting this infrastructure is 
often a property that needs to be rented out at a cost that will be borne by individual 
patient (Table 5). Furthermore, the FMHS of Stellenbosch University contributed 
towards the laboratory infrastructure development through the purchase of the 
incubator, and the private clinic (Drs Aevitas) also donated the old ICSI machine and 
incubator to the laboratory. These are significant contributions that have to be 
acknowledged, especially when the actual cost of this equipment is known to be in the 
millions [8]. As previously mentioned, the interaction may not necessarily be ongoing, 
but a once off contribution that is significant and meaningful is also recognized. In this 
regard the contribution by Tygerberg Hospital (providing infrastructure at a low cost to 
the patients), the Stellenbosch University FMHS and Drs Aevitas (providing necessary 
and expensive equipment at no cost to patients) is a point in illustration on how PPI 
contributes to lowering the cost of ART in the long term as there are no loans to be 
repaid. These interactions have been observed in other countries like Brazil [26]. 
Although ICSI treatment might be required for severe male infertility, during the initial 
set-up IVF is sufficient to provide the necessary service, especially as the majority of 
infertility is caused by tubal factors (45.6%). 
 
Personnel or staff competence and commitment is vital to successful implementation 
of effective ART services [27]. In this current model the certified reproductive medicine 
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specialists and embryologists are the employees of the University and the Government 
respectively. Therefore their remuneration is fully subsidised by their respective 
employers at no direct cost to patients (Table 5). In the private setting the clinician’s 
fees and consultation contribute 29% (R14 500 / 1 120 USD) towards IVF cost, and 
this is a direct cost to the individual couple. There are no IVF sisters, nurses or co-
ordinators in this currently presented model, which required an additional effort from 
the available staff to co-ordinate and provide the service. In this regard, it is Tygerberg 
Hospital and Stellenbosch University FMHS (governmental, public institutions) 
contributing towards lowering the direct costs of IVF to individual couples. At the 
beginning, the service can adequately be performed by one doctor and one 
embryologist. 
 
In this study, we used a combination of CC and hMG for ovarian stimulation at a cost 
of R3 500–R4 000 (270-308 USD) (Figure 1) as opposed to conventional ovarian 
stimulation at a cost of R14 000 (1 081 USD) [8]. Mild ovarian stimulation protocols 
are defined in the literature [28,29] and their associated advantages and 
disadvantages are also well expressed [30,31]. We did not use the GnRH antagonist 
in this protocol as a measure to lower the cost of treatment. Similar protocols such as 
ours have been used with reasonable success [32]. The cycles in this current model 
were monitored with an ultrasound and urinary LH test only. Due to lack of clear 
evidence to suggest any significant benefit in improving IVF outcome or predicting 
OHSS probability, the biochemical endocrine blood tests were not performed [33,34]. 
Palmer et al. have shown with a high degree of sensitivity that urine LH tests can 
predict ovulation in advance [35]. The cost of oocyte retrieval was also lowered quite 
significantly, by performing the procedure in the ART laboratory with adequate 
monitoring and resuscitation facilities nearby. The patients were offered 100mg of 
pethidine injection 15-30 minutes before procedure and were also injected locally with 
1% Lignocaine at the puncture site. This approach eliminated the need for a theatre 
and anaesthetist (Table 5). 
 
Laboratory costs account for 35% (R17 500 / 1 351 USD) of the IVF cycle in private 
clinics [8]. In our model the couple pay for consumables such as media, plastics and 
slides on average R364 (28 USD) per cycle of IVF/ICSI. There are no costs related to 
theatre set-up and an anaesthetist for oocyte retrieval as described above.  Again, the 
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doctors administering conscious sedation medication are the ones performing the 
oocyte retrieval, and the embryologist performs the role of the nurse as well. This is a 
significant way of further lowering the cost of IVF. This is a contribution by Tygerberg 
Hospital and Stellenbosch University FMHS (governmental, public institutions) by 
providing the necessary human resource and platform to perform ART procedures 
safely. The patients will also pay an additional fee of R500 (38.60 USD) for ICSI 
pipettes if necessary. More often, we use the sterilized aspiration needles and embryo 
transfer catheters to further lower the cost of treatment without compromising patient 
safety and results. The patients are always informed about the method and given an 
option to purchase new apparatus if so wish. These consumables are received from 
the private clinic following single use and they will undergo a rigorous cleaning and 
sterilization process with gamma radiation at a dose of 18 kilo Gray (kGy) [36-39]. 
Without this interaction with private clinic, the patients would be forced to buy new 
apparatus for every cycle of IVF/ICSI. This is another illustration on how PPI 
contributes towards lowering the cost of ART treatment. The total minimum cost of the 
IVF/ICSI cycle could amount to R122 326 (9 446 USD) in the public unit versus R187 
000 (14 440 USD) in the private facility, and the couple’s direct cost to treatment is 
approximately R7 291 (563 USD) versus R51 024 (3940 USD) for public and private 
facilities respectively (Table 6). These figures illustrate the significant contribution 
made by the government (hospital and/or university) through participation and 
commitment in the model together with the involvement of the private sector in 
lowering the cost of IVF treatment to individual state patients. It is important to note 
that the cost of ART services did not exceed 0.25% of total healthcare expenditure in 
any country providing this kind of service [4].  
 
The breakdown of individual cost per cycle was:  
 hospital visits (max 5) = R1 205 (93 USD) 
 medication (stimulation and luteal support) = R3 500 (270 USD) 
 laboratory fees = R1 427 (110 USD) 
 plus R500 (39 USD) for pipettes. 
 
During the study period 92% of started cycles reached an oocyte retrieval stage. We 
did not have a policy of cancelling the cycles based on the number of follicles, or 
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positive LH test before HCG administration. The mean number of oocytes retrieved 
per cycle was 4.3 ± 4.0, which is lower than the number of oocytes collected in 
conventional IVF. Sunkara et al. reported that approximately 15 eggs are required in 
conventional IVF cycles to improve the live birth rate [40]. Despite the low number of 
oocytes retrieved, the mean number of good quality embryos available for transfer on 
day 2/3 in this study was 2.09 ± 2.36 / 2.02 ± 2.01 respectively. Similar findings of a 
lower number of oocytes retrieved during mild ovarian stimulation cycle but which 
yielded a higher number of good quality embryos and satisfactory pregnancy results, 
were observed in a randomised controlled trial by Hohmann et al. [31]. Therefore other 
variables besides the number of oocytes associated with pregnancy outcomes in IVF 
should always be evaluated. The clinical pregnancy rate of 14.1% per started cycle 
and 23.5% per ET were achieved. These results are similar to those reported in the 
previous studies [22,41-43]. The live birth rates in this study were 10.6% per cycle and 
17.7% per ET. Similar outcomes were observed in an affordable IVF study by 
Aleyamma et al. [22]. Williams et al. have reported ongoing pregnancy rates of 30% 
with a similar protocol, but no LBR were reported [32]. For women under the age of 35 
years, in the public sector (low cost model) vs the ones in the private sector 
(conventional IVF, SARA report) [9], the clinical pregnancy rates per ET were 
significantly higher in the private sector group; 40% (private) [9] vs 25.4% (public), 
p=0.0041 (Table 3). Similarly in women >35 yrs of age the results were significantly 
better in favour of conventional IVF in the private sector, 32% (private) [9] vs 18.9% 
(public), p=0.01 (Table 3). This therefore suggests that if a couple can afford the 
private fees, the conventional IVF would be the recommended approach. 
 
The proportion of absent oocytes at the time of aspiration was high in this study despite 
the presence of expected number of follicles. This finding does stimulate the debate 
around follicle flushing in patients with a lesser number of follicles [44]. Because of 
limited available evidence this is not a protocol in our unit and therefore a randomised 
controlled trial with the aim to evaluate the benefit of this strategy in the setting of a 
low number of oocytes is much needed. High fertilization failure rates (65.5%) were 
observed in IVF treatment cycles in this study despite the normal semen parameters. 
These findings may reflect the probability of poor oocyte quality. However there is also 
a possibility that ICSI would have resulted better fertilization rates, especially when 
dealing with a low number of oocytes. But this notion is not supported by the current 
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available evidence, that ICSI provides any additional benefit to couples with few 
oocytes in ART treatment [45,46]. Therefore severe male infertility should remain the 
primary indication for ICSI treatment. The cycle cancellations as a result of poor 
follicular development occurred more frequently in patients with PCOS, previous 
cystectomy for endometrioma and advanced female age of >38yrs old. It is therefore 
important to select the patients who would benefit from the mild ovarian stimulation 
regimen carefully and appropriately and further advise on the role of ovarian reserve 
testing and the need for timeous conventional ovarian stimulation IVF. 
 
This low cost model study further shows that there were 237 first attempt cycles of 
ART and only 37 (9.8%) cycles were third time attempts, clearly demonstrating a 
significant drop in the number of treatment attempts. The financial limitation as a 
strong barrier towards treatment accessibility was the primary reason for the significant 
drop since the majority of the patients could not afford the second, let alone the third 
cycle of IVF (Table 2). In this study the couple had a 14.1% chance of pregnancy after 
the first cycle of ART, 19.8% after the second cycle and 31.7% after the third cycle 
(Figure 2). It means that for a couple to achieve results above 30% of pregnancy in a 
low cost model, they will need at least three cycles of ART, and this will cost them 
approximately R22 000 (1 698 USD). The probability of any significant improvement 
(above 32%) in pregnancy result may be realised after the sixth cycle of IVF (Figure 
2). But it is also known that IVF does not guarantee success, with almost 50% of 
couples starting treatment who will remain childless, even if they undergo six cycles 
of IVF [19]. The available knowledge regarding ART treatment is that a plateau will be 
reached following 4 cycles, and the present standard of care is to consider other 
options beyond the 4th cycle. The index study shows a plateau (Table 4, Figure 2) 
following three cycles with a total of 22 attempts in cycles 4 to 6. Women in the public 
sector should be encouraged to budget for 3 cycles until more information is available. 
This study demonstrates that even though the pregnancy outcomes are lower in the 
low cost model than in conventional IVF, the model does provide access and hope to 
those couples who might not have had a chance at all to try and possibly succeed with 
IVF. And factors such as hydrosalpinx and increased body weight should be dealt with 
prior to initiation of ART treatment as they were some of the factors thought to be 
negatively affecting the pregnancy outcomes in this study. 
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There were only three sets of twins (5.6%) observed throughout the study period and 
no cases of OHSS were reported. The rates of ART-conceived multiple births in the 
USA were reported to be above 40% in 2012 [47]. Furthermore, the medical costs 
were frightening, with ART singleton deliveries estimated at 26 922 USD versus  
115 238 USD for ART twin deliveries (4 times) [48]. Similar findings were reported by 
Lukassen et al. [49]. There were no reported rates of multiple pregnancies in the South 
African ART registry report [9]. It is important to recognize that even in the low cost 
ART, a 26% rate of multiple pregnancies was reported and this is high [22]. This 
indicates and affirms that the individual consumer payment for ART not only influences 
access to treatment but also policies on the number of embryos to transfer [6]. Several 
studies have shown that in countries where governments are involved with public 
funding for ART and policy making, the benefits have been overwhelming. The 
programmes have shown a significant reduction in multiple pregnancy rates 
[3,17,50,51]. In poorly resourced countries with overburdened services, the negative 
outcomes of treatment should be avoided at all costs. It therefore makes it a primary 
goal of all involved with the care of healthy subfertile women to make it safe and 
minimize the financial burden of high order multiple pregnancies. 
 
Provision of affordable ART services is certainly a worthy endeavour that should be 
supported and nurtured to increase access to treatment. This will further promote the 
Millennium Development Goals of achieving universal access to reproductive health 
by 2015 [52]. Beyond providing simple access to treatment, ART has been shown to 
reduce the risk of HIV transmission in serodiscordant partners. The number of people 
living with HIV worldwide continued to grow in 2010, reaching an estimated 35 million 
with approximately 2.7 million new infections [53]. According to the WHO, over half of 
people living with HIV are women, mostly of reproductive age, and they are the most 
vulnerable and marginalised when dealing with issues of infertility and procreation [54]. 
With evidence to show that ART can reduce the risk of contamination of the uninfected 
partner and help couples to conceive under safe circumstances, it thus further 
proposes a strong argument to make ART affordable and accessible in order to protect 
the uninfected partner in a heterosexual relationship [55-57]. The availability of ART 
service in the public hospital, particularly a teaching hospital, also provided a platform 
beyond just service delivery by allowing us the opportunity to continue to promote and 
improve teaching and training of reproductive medicine sub-specialists (currently four 
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in our programme), resident (registrars) rotating through infertility training and 
reproductive biology student, embryologist (currently two in training). 
 
In conclusion, PPI as illustrated in this study, appeared to make ART accessible and 
allowed couples the opportunity to undergo treatment, therefore presenting a viable 
strategy towards ART provision in limited resource settings. In our opinion, this model 
can be reproduced and be implemented successfully in developing countries. 
However, further research should continue to evaluate and analyse the outcomes of 
other affordable methods of ART such as uterine-sperm-egg transfer [58], INVO Cell 
[59] and the tWE [60] in large clinical trials. 
 
This full study, PPI model and description of patients treated is submitted for 
publication to Human Reproduction.  
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Table 1: Patient demographic characteristics 
Variables Mean ± SD 
Age (years) 
BMI                                                                                            
34.9 ± 4.7  
29.8 ± 2.4 
Infertility diagnosis 
 Tubal factor 
 Teratozoospermia 
 PCOS  
 Endometriosis  
 Unexplained  
 Others                      
 
159 (45.6) 
100 (28.6) 
 20  ( 5.7) 
 12  (3.4) 
 52  (14.9) 
 6    (1.7) 
BMI (kg/m2) 
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Table 2: Clinical outcomes  
Variables Available literature  
(local private data) 
N (%) 
Total number of 1st cycle  237 
Total number of 2nd cycles  79 
Total number of 3rd cycles  37 
Total number of cycles performed  375 
 
Number of cycles reached oocyte retrieval stage 
 
346 (92%) 
 
Fertilization rate 
  
251 (72.5%) 
 
Mean number of oocytes retrieved 
  
4.3 ± 4.0 
Mean number of embryos transferred  2.99 ± 0.93 
Mean number of good quality embryos on the day of transfer 
: day 2 
: day 3 
 
2.09 ± 2.36 
2.02 ±  2.01 
 
Average day of embryo transfer 
  
1.27 ± 1.62 
 
Cycles cancelled 
  
150 (40%) 
 
Reasons for cycles cancellation 
 No follicular development 
 No oocytes at aspiration 
 No fertilization 
 Poor quality embryo 
  
 
29/375 (7.7%) 
37/346 (10.7%) 
58/346 (16.7%) 
26/346 (7.5%) 
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Table 3: Treatment outcomes 
Variables: N (%) Data from SARA [9] 
Clinical pregnancy/cycle 53/375 (14.1%)  
 
Clinical pregnancy/transfer 
 
53/225 (23.5%) 
 
 
Clinical pregnancy/ET in women <35 yrs 
 
29/114 (25.4%) 
*P=0.0041 
 
584/1499 (40%) 
 
 
Clinical pregnancy/ET in women >35 yrs 
 
21/111 (18.9%) 
*P=0.01 
 
390/1314 (29.6%) 
 
 
Miscarriage rate  
 
12/53 (22.6%) 
 
 
Ectopic pregnancy rate 
 
1/53 (1.9%) 
 
 
 
Live birth rate/cycle 
 
40/375 (10.6%) 
 
 
Live birth rate / ET 
 
40/225 (17.7%) 
 
 
Multiple pregnancy rate: 
 Triplets 
 Twins 
 
 
NIL 
3/53 (5.6%) 
 
 
OHSS 
 
NIL 
 
 
IVF 
 
202 (53.8%) 
 
 
ICSI 
 
167 (44.5%) 
 
 
IVF + ICSI 
 
6 (1.6%) 
 
 
Stellenbosch University  https://scholar.sun.ac.za
108 
 
Table 4: Kaplan – Meier estimates of pregnancy per number of ART cycles 
 
 
Cycles 
 
Interval 
Begin 
 
Total 
Pregnancies Cumulative 
Pregnancy rates 
Std. 
Error 
95% Conf. Int. 
 237 24 0.1412 0.0267 0.0969      0.2032 
2 79 4 0.1984 0.0372 0.1363      0.2838 
3 37 4 0.3172 0.0633 0.2110      0.4590 
4 13 0 0.3172 0.0633 0.2110      0.4590 
5 5 0 0.3172 0.0633 0.2110      0.4590 
6 4 0 0.3172 0.0633 0.2110      0.4590 
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Table 5:  Cost comparison of ART cycles between public and private sector services   
Variables Public sector (Tygerberg Unit) Private sector 
Infrastructure (clinic + laboratory facility) Hospital facility billing accordingly to hospital 
policy (UPFS) 
Rental fees on average ± R15 000 / month 
OR R4000 clinic fees [8]** 
 
Personnel: 
 Doctor’s fees – Reproductive Medicine            
Specialist (on average 2 per clinic ) 
 
 
 
R50 – 70 000 / month x 2            
 
 
R80 000 / month x 3 
Maybe more  
R14 500 direct cost to patient [8]** 
 Embryologist – Senior 
                      - Junior 
R20 – 25 000 / month 
R15 – 20 000/ month 
R50 000/month 
R30 000/month 
 IVF sister (Subspecialist rates) R20 - 25 000/month – N/A R25 000/month 
 IVF nurses R4 000 – 6 000/month – N/A R8 000/month (x 2-4) 
 Receptionist/co-ordinators R5 000 – R10 000/month – N/A R15 000/month (x 5) 
 Cleaners 
 
R2 000 – R5 000/month – N/A R4 000/month 
 
Medication 
 
Mild stimulation protocol, including Luteal 
Support R3 500 – R4 500.00 
 
± R15 000.00 [8]** 
 
 
Oocyte retrieval 
 Doctors costs/fees  
 Day ward, theatre, anaesthetist  
 
 
R0.00 
Hospital billing fees (UPFS) 
 Pethidine Injection 100mg = R20.16 
 Lignocaine 1 - 2%,  20 ml local block 
R142.06 for 10 (R14.06) 
 
 
 
Included in the laboratory costs 
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Laboratory costs + transfer 
Consumables including aspiration needles, 
Plastics, slides, pipettes, dishes, sperm 
prep 
 ICSI pipettes. 
*Aspiration needles + ET catheters  
 
R363.03 
 
 
R500.00 
R927.92 
 
R17 500.00 [8]** 
 
 
Cycle monitoring  
 
Ultrasound 
Oestradiol + LH tests  
 
 
 
 
 
R0.00 
R0.00 
 
 
 
 
R1 610.00 
R400.00 
 
 
Grand total 
 
R121 326.00 - R167 326.00 
 
 
R246 100.00α 
 
 
Direct cost to patient 
 
Subsidised: 
 
R7 291 (Direct) 
 
R115 035 – 161 035 
 
R51 000.00 (Direct cost to patient) 
 
Cost of IVF/ICSI cycle 
 
R6 000 – 8 000 
 
R35 000.00- R50 000 [8]*** 
 
Subsidised costs 
 
R121 322 – 167 320 
 
None 
UPFS = Uniform Patient Fees Schedule, * Not always new, ** Direct costs to patients in 2012, there could be new figures, *** Price tag of IVF 
cycle which vary from clinic to clinic, α Estimated costs to company (clinic) based on one personnel in human resource categories (multiply by 
added number where applicable in big clinics). This cost is excluding medication and blood test fees.  
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Figure 1: Stimulation protocol 
Stimulation protocol: Combination of Clomiphene Citrate and Menopur (75IU 
FSH& 75IU LH)  
Treatment day 1 2 3 4 5 6 7 8 9 
CC (100mg)   X X X X X   
Menopur(150-225IU)   X  X  X  
Ultrasound Pre-treatment / AFC   X  
Urine LH       X 
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Figure 2:  Kaplan-Meier graph, probability of pregnancy per number of ART cycles 
 
p
ro
p
o
rt
io
n
 p
re
g
n
a
n
t
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
0 1 2 3 4 5 6
number of cycles
Stellenbosch University  https://scholar.sun.ac.za
113 
 
Addendum A: Signed Level of Agreement (SLA) 
 
Provincial Government Western Cape - Department of Health - Tygerberg Hospital 
 
 
SERVICE LEVEL AGREEMENT 
 
 
Entered into between 
 
TYGERBERG HOSPITAL 
 
Represented by Dr D. Erasmus 
in his capacity as Chief Executive Officer of Tygerberg Hospital 
 
 
AND 
 
 
AEVITAS CLINIC 
 
Herein represented by Prof Thinus Kruger, 
who warrants that he is duly authorised thereto 
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Background 
 
This IVF service will be to the benefit of the community at large and with no significant cost 
to the State and Tygerberg Hospital. The programmes available in the private sector run at 
a cost between R25 000 to R35 000 per case and at Groote Schuur Hospital at R12 000 per 
case. This venture will render a cost effective service for patients in our region. 
 
1. PURPOSE 
 
To supply an in vitro fertilization service (test tube baby service) to patients in the Easter 
Metro pole as well as other patients in need for assisted reproductive technology (ART). 
 
2. OBJECTIVES 
 
 To render a low cost IVF service with minimal impact on the state resources to patients 
in need.  
 To achieve universal access to reproductive health for patients in our region and those 
in need for fertility services in line with the United Nations Millennium Development 
Goals 
 
3. PROCEDURE 
 
3.1. Patients will be followed by an ART specialist with ultrasound and oocytes will be 
matured using the injection Ovitrelle. 
3.2. IVF (test tube treatment) is done in the following way: 
 Ovulation induction induced with CC and 3 ampoules of MMG 
 Egg harvesting done under local block in the IVF laboratory. 
 Embryo culture will take place in an incubator available in the IVF laboratory. 
 Embryo transfer will be performed in the same area.  
 With low cost IVF no ward or theatre will be used, saving a lot of cost. 
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4. SERVICE FREQUENCY AND STAFFING REQUIREMENTS 
 
 The clinic will operate on a day to day basis 
 5-10 cases per month will be seen at the clinic 
 Dr  Thabo Matsaseng –– University of Stellenbosch Scholarship and rendering a 
service to Tygerberg Hospital with permission of the authorities 
 Dr Maria Viola - University of Stellenbosch Scholarship and rendering a service to 
Tygerberg Hospital with permission of the authorities. 
 Social Worker – To be arranged by Aevitas Clinic Staff if required. 
 
5. VENUE FOR THE PROVISION OF SERVICE 
 
 Follow-up will happen at the ultrasound area, 3rd floor, Gynae outpatients.  
 IVF treatment on the second floor in the existing IVF laboratory. 
 
6. BILLING  
 
6.1 For the infertility visit at Tygerberg outpatient department, patients will be billed by 
Tygerberg Hospital an amount equivalent of an OPD visit, in accordance to the Uniform 
Patient Fees Schedule (UPFS).  
 
6.2 For the IVF service rendered, patients will directly be billed by the training unit of the 
US (Aevitas Clinic).  
 
Currently the patients will pay an amount of R5000 to R8 500 per case, depended on the 
amount of medication used.  
 
  
Stellenbosch University  https://scholar.sun.ac.za
116 
 
Category 1: Patients qualifying for full subsidization: 
Ho = no payment 
 
Category 2: Patients qualifying partial subsidization (H1, H2, H3) 
H1=R35 
H2=R120 
H3=R194 
 
Category 3: Full paying patients (No subsidy)  
This category of patients includes but is not limited to externally funded patients. 
Non-South African citizens/Foreigners may be included. Full paying patients are 
liable for the full UPFS fee.   
Tariff - Equivalent to a visit fee: 
Private(P) - R241 
 
Prescribed Minimum benefits(PMB/s): Infertility Code: 902M 
Infertility is currently listed as a Prescribed Minimum Benefit (PMB) condition in the 
Medical Schemes Act 131 of 1998 under the category Female Reproductive System.  
Medical schemes are legally obliged to provide these Prescribed Minimum Benefits 
regardless of the member’s package.  
 
Pre-authorization/Authorization 
All externally funded patients, i.e. confirmed medical scheme patients, including state 
departments patients attending public health institutions whereby the rule compels 
authorization / pre-authorization, shall ensure that the aforementioned is obtained. 
The onus is on the respective patient to obtain the authorization (pre-authorization) 
number, and is not the responsibility of the public health institutions to ensure the 
above.  
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7. CONSUMABLES AVAILABILITY 
 
Aevitas Clinic, registered as a training facility of University Stellenbosch, will supply the 
following: 
 
 Medication 
 Medical Personal ( ART specialists) to service to the patients 
 Needles to harvest the eggs 
 Growth medium for the embryos and semen preparation, plastic ware to use for 
embryo culture and semen preparation 
 Embryo transfer catheters 
 All other consumables  
 
8. REVIEW OF THE CONTRACT 
 
Neither the benefits nor the obligations under this SLA may be ceded or assigned by either 
party except with the prior consent of the other party. 
The SLA will thus be reviewed every 3 or 6 months should the two parties deem it necessary. 
 
9. INDEMNITY 
 
The Service Provider agrees to hold Tygerberg Hospital harmless and indemnified, for the 
duration of this SLA, against all actions, litigations, demands, suits, proceedings (and all 
associated costs / expenses) which may be pursued against TBH arising from any real or 
perceived injury or damage or loss of property or death or injury caused to any persons 
during or as a result of the services agreed to in this SLA. 
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SIGNED at _______________________ on this __ day of ________________ 2007. 
 
 
WITNESSES:  ________________________ 
 DR D. ERASMUS 
 Chief Director 
 Tygerberg hospital 
 Private Bag X1 
 TYGERBERG 
 7505 
 
 
 
___________________________________________________________________ 
 
Service Provider 
 
 
SIGNED at _______________________ on this __ day of ________________ 2007. 
 
 
WITNESSES: 
 
1. ____________________________ 
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CHAPTER 5: MILD OVARIAN STIMULATION FOR IN VITRO FERTILIZATION: ARE WE 
READY TO CHANGE? A META-ANALYSIS 
 
SYNOPSIS 
 
Objective: To compare the efficacy of mild ovarian stimulation versus conventional 
stimulation in IVF. 
 
Design: Meta-analysis 
 
Search strategy: A systemic literature search was carried out for prospective randomised 
clinical trials. We searched electronically using Pubmed, Medline and Embase for all studies 
published from 1990 to December 2011. 
 
Interventions: Mild ovarian stimulation IVF, which uses lower doses and/or shorter duration 
of gonadotrophins in GnRH antagonist co-treated cycle compared with conventional 
stimulation IVF.  
 
Main outcome measures: LBR per started cycle and OPR per started cycle of IVF 
 
Results: A total of 148 patients per 769 cycles (70 mild and 78 conventional) showed a 
significant difference in favour of conventional ovarian stimulation for LBR [OR=0.59, CI: 
0.41-0.85, P=0.004, Fig.1a]. Similar findings were observed in the ongoing pregnancy data 
of 284 patients per 1243 cycles (140 mild and 144 conventional) with significant difference 
in favour of conventional stimulation protocols [OR=0.72, CI: 0.55-0.93, P=0.01, Fig.1b]. The 
sub-analysis of two studies showed statistically significant reduction of hyperstimulation 
syndrome in favour of the mild stimulation [OR=0.27, CI: 0.11-0.66]. 
 
Conclusion: This analysis presents strong evidence in favour of conventional stimulation 
IVF and therefore should currently be considered a treatment of choice for patients requiring 
IVF treatment. 
 
Keywords: IVF, ICSI, mild ovarian stimulation, conventional stimulation IVF, Clomiphene 
Citrate, live birth rate, ongoing pregnancy rate, treatment outcomes  
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INTRODUCTION 
 
A recent publication by Sir Howard Jones reported on seven roads travelled to make 
assisted reproductive technology (ART) the success it is today, and suggested seven more 
roads to be travelled to continue to improve it [1]. Among them is to make ART safe, 
accessible and available to most infertile couples [1]. Furthermore it is a public health 
challenge to make ART available, affordable and accessible with minimal adverse effects 
without compromising its effectiveness.  
 
Conventional ovarian stimulation protocol aims to provide the maximum number of oocytes 
retrieved for fertilization and thus several embryos for selection and transfer [2]. However, it 
is not without complications. The prevalence of potentially fatal severe OHSS is reported to 
be 0,5 – 5% [3]. Together with high order multiple gestation, OHSS remains a huge problem 
in ART treatments with significant morbidity and financial burden on health resources [4,5]. 
Pinborg et al. reported that 40% of children born following ART are twins, and these babies 
had a 7.4-fold increase in delivery before 32 weeks of gestation with significant increase in 
the admission to neonatal intensive care units [6]. The supra-physiological levels of steroid 
hormones seen in conventional ovarian stimulation are associated with adverse effects on 
endometrial receptivity [7] and may result in accentuated maturation of the endometrium, 
leading to embryo-endometrial asynchrony and reduced implantation rates [8]. Similar 
detrimental effects have also been associated with oocytes and embryo abnormalities [9,10]. 
The complexity of the long protocol, time consumption, patient discomfort, high costs and 
emotional distress are further associated with high drop-out rates from IVF / ICSI cycles [11-
13]. 
 
The ideology that obtaining an increased number of oocytes leads to better pregnancy rates 
might be unjustified and contradictory [14]. Studies that evaluated the relationship between 
the number of oocytes retrieved and the pregnancy outcomes, reported an increase in 
pregnancy rates with a maximum of 15 eggs [15,16] and eventually a plateau or the decline 
in positive outcomes with an excess beyond this number of oocytes [16-18]. Furthermore, a 
recent meta-analysis suggests that the retrieval of a modest number of oocytes following 
mild stimulation is associated with higher implantation rates compared with patients where 
the same number of oocytes is retrieved following conventional stimulation [19]. Data 
suggest comparable outcomes between mild ovarian stimulation and conventional 
stimulation protocols but fewer complications, lower costs, and significantly fewer drop-outs 
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in mild protocols [11,12,20]. There is merit in considering these patient friendly approaches. 
To facilitate the acceptance and implementation of these strategies, we have decided to 
review all the published prospectively randomised papers that seek to evaluate the 
pregnancy outcomes in mild ovarian stimulation protocol versus conventional stimulation 
protocol. 
 
Materials and Methods  
 
Search strategy and identification of literature  
A computerized literature search of all reports which described randomised controlled trials 
and prospective comparative trials of mild ovarian stimulation versus conventional 
stimulation was performed via Pubmed, Medline (1990 – 31 December 2011) and Embase 
(1990 – 31 December 2011). Relevant additional articles were hand-searched. A 
combination of medical subject headings (MeSH) and text words were used to generate 
subsets of citation such as ‘mild ovarian stimulation’, ‘minimal ovarian stimulation’, ‘ovarian 
stimulation protocol’, ‘patient friendly strategies’, ‘soft stimulation’, ‘low ovarian response’ 
and ‘IVF or ICSI’. The menstrual disorders and subfertility group specialised register of 
controlled trials was also searched. The search was limited to trials in humans only. No 
language restrictions were placed on any search. The searches were conducted 
independently by TM and TFK. No written protocol of this review has been made or 
published. 
 
Definitions 
 
Mild stimulation in vitro fertilization 
A mild cycle is defined as the method when FSH or HMG is administered at lower doses, 
and/or for a shorter duration in a GnRH antagonist co-treated cycle, or when oral compounds 
[anti-oestrogen or aromatase inhibitors] are used either alone or in combination with 
gonadotrophins with the aim of collecting a lower number of oocytes [21,22,23]. 
 
Conventional stimulation in vitro fertilization 
This is defined as the term when a GnRH agonist is used for pituitary down-regulation 
followed by conventional doses of stimulation with FSH or HMG, or when a GnRH agonist 
is administered in a flare protocol with conventional doses of FSH or HMG, or when a GnRH 
antagonist is used with conventional doses of early start of FSH or HMG [21-23]. 
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Study selection and data collection 
 
Inclusion criteria 
Studies were included if they reported the pregnancy outcomes in patients treated with mild 
ovarian stimulation compared to those treated with conventional stimulation protocols. All 
prospective randomised trials were included including those involving women below 38 
years of age, regular menstrual cycle (25-35days), BMI of 18-29kg/m2, normal hormonal 
profile and absence of uterine or ovarian abnormalities.  
 
Exclusion criteria 
Studies involving natural cycle conception, modified natural cycle conception, mild ovarian 
stimulation in a poor responder, oocyte donation, embryo donation and intra-uterine 
inseminations were excluded.  
 
The following data collected from all the trials included: patient demographics, pattern of 
menstrual cycle, ovarian stimulation protocol, the number of oocytes retrieved, insemination 
technique [IVF/ICSI], fertilization rates, the number of embryos transferred, the clinical 
pregnancy rates, the ongoing pregnancy rates, and the live birth rates where available.  
 
Outcome measures 
 
The ideal primary outcome measure is the live birth rate. However, due to differences in the 
studies regarding the number of embryos transferred and the measure of their outcomes, 
the chosen primary outcome measure is the ongoing pregnancy rate. Other outcome 
measures such as clinical pregnancy rates, number of oocytes retrieved, number of embryos 
transferred, cycle cancellation rates, and complications such as OHSS were also studied 
and reported where possible. For the purpose of this review, clinical pregnancy rate was 
defined as the presence of the foetal heart beat on ultrasound at seven weeks of gestation, 
and the ongoing pregnancy rate was defined as the presence of the foetal heart beat on 
ultrasound at 12 weeks of gestation. 
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Data and statistical analysis 
 
A score was allocated to each trial using the validated scoring system [24]. Six 
methodological variables such as randomization, group demographics, placebo use, follow-
up, co-intervention and patient and cycle differentiation were chosen (Table1). Each trial 
was assessed and ranked for its methodological conduct and its potential to introduce bias. 
Trials were allocated scores that were divided by maximum possible and a percentage 
performance was given to each trial. Performance scores ranged from 79% to 100% 
(Table2). The data on the outcomes of each trial were summarized in two-by-two tables. 
The Peto odds ratio (OR) with its 95% confidence interval (CI) was calculated as the odds 
of an event in the mild stimulation group divided by the odds of an event in the conventional 
stimulation group in IVF/ICSI treatment. Statistical significance was inferred when the OR 
did not include 1.  
 
The weight of each study in each analysis was calculated as inversely proportional to the 
variance. The degree of heterogeneity of studies was calculated using the chi-square test, 
with the p-value of <0.05 considered the limit of statistical significance, and I2 statistics was 
used to describe the percentage of total variation across studies. An I2 value of 0% was 
considered to signify no observed heterogeneity, while the values of 25, 50 and 75% were 
considered to indicate low, moderate and severe degrees of heterogeneity respectively. The 
applicable studies were re-analysed to find an explanation for any differences and also 
applied RevMan software to do a fixed effect meta-analysis. Analyses were performed using 
SPSS version 12.0 (SPSS Inc., Chicago, IL, USA, 1999).  
 
Results 
 
Our search strategy identified 68 citations. Following the reading and scrutiny of the 
manuscripts, 43 studies were excluded by title and abstract and 20 did not meet the inclusion 
criteria by protocol. Therefore five studies met the inclusion criteria and were analysed. The 
characteristics of all the included studies are listed in Table 3. All five studies included were 
prospective and randomised. They were all approved by the local ethics committees.  
 
The patient characteristics were comparable for all the studies, including regular indications 
for IVF/ICSI, age below 38 years, regular menstrual cycles (25-35 days) and absence of 
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severe endometriosis and uterine abnormalities. In these studies mild ovarian stimulation 
[21-23] was compared with conventional ovarian stimulation for IVF/ICSI. 
 
The primary outcomes were live birth rates and ongoing pregnancy rates per cycle started. 
The secondary outcomes such as number of oocytes retrieved, total number of 
gonadotrophins used, cycle cancellation rates and OHSS rates were also reported.  
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Table 1: Validity criteria and scoring for methodology assessment of studies 
Category Score Method 
A Randomization 3 
2 
1 
Randomized by central means [telephone and pharmacy] or sealed envelopes 
Alternating numbers 
Methods not described 
B Group demographics 2 
1 
Demographics comparable 
Demographics not described 
C Placebo use 2 
1 
Placebo or other treatment used in control group 
No placebo or other treatment 
D Follow up 2 
1 
Outcome data for primary analysis complete 
Outcome data incomplete 
E Co-intervention 2 
1 
Other than for use of treatment versus control, protocol involved same drugs 
Difference in protocols that may lead to contaminated results 
F Patient and cycle   
   differentiation 
3 
2 
1 
Only first treatment cycle included 
Patients included for more than 1 cycle 
Cycles and patients not differentiated 
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Table 2: Validity criteria score for each selected trial 
 
Study Score 
% 
Randomization Demographics Placebo/ 
Other 
Follow 
up 
Co-
intervention 
Cycles 
Baart et al, 2007 100 3 2 2 2 2 3 
Blockeel et al, 2011 100 3 2 2 2 2 3 
Heijnen et al, 2007 100 3 2 2 2 2 3 
Hohmann et al, 2003 93 3 2 2 2 2 2 
Karimzadeh et al, 2010 100 3 2 2 2 2 3 
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Table 3: Characteristics of included studies 
 
  
Study Design Inclusion criteria Study protocol [mild stimulation] Control stimulation 
protocol[conventional] 
Baart et al. 
2007 
RCT Women below 38yrs of age, regular 
indication for IVF, regular menstrual cycle, 
BMI of 19-29kg/m², sperm count > 5mil/ml, 
no previous IVF cycle not resulting embryo 
transfer and no uterine or ovarian 
abnormalities.  
Fixed 150IU/day of FSH from cycle day 
5. GnRH antagonist 0.25mg/day was 
initiated when the leading follicle is 
14mm  
Long GnRH agonist for 
2weeks and then fixed 
doses of 225IU/day of FSH 
 
Blockeel et al.  
2011 
RCT Regular indications for IVF, Age between 
18-36yrs, BMI of 18-29kg/m², regular 
menstrual cycle, normal CD 2 FSH, no 
PCOS and no severe endometriosis.  
Fixed 150IU/day of FSH from cycle day 
5. GnRH antagonist 0.25mg/day was 
initiated on CD6 
Fixed 150IU/day of FSH 
from cycle day 2. GnRH 
antagonist 0.25mg/day was 
initiated on CD6 
Heijnen et al. 
2007 
Parallel group, 
non-inferiority 
randomised trial 
Regular indication for IVF or ICSI, menstrual 
cycle length of 25-35days, BMI of 18-
28kg/m², Age <38yrs, no previous IVF or 
healthy born child from IVF 
Fixed 150IU/day of FSH from cycle day 
5. GnRH antagonist 0.25mg/day was 
initiated when the leading follicle is 
14mm. Combined with single embryo 
transfer. 
Long GnRH agonist for 
2weeks and then fixed 
doses of 150IU/day of FSH 
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Study Design Inclusion criteria Study protocol [mild stimulation] Control stimulation 
protocol[conventional] 
Hohmann 
et al. 
2003 
Prospective 
randomised trial 
Regular indication for IVF or ICSI, BMI of 
19-29kg/m², Age 20-38yrs, regular 
menstrual cycle, no severe endometriosis or 
uterine or ovarian abnormalities, no more 
than three previous IVF cycles, no previous 
cycle with poor response or OHSS.  
Fixed 150IU/day of FSH from cycle day 
5. GnRH antagonist 0.25mg/day was 
initiated when the leading follicle is 
14mm. 
Long GnRH agonist for 
2weeks and then fixed doses 
of 150IU/day of FSH   
or 
Fixed 150IU/day of FSH 
from cycle day 2. GnRH 
antagonist 0.25mg/day was 
initiated when the leading 
follicle is 14mm. 
 
Karimzad
eh et al. 
2010 
Prospective 
randomised 
controlled trial 
First IVF attempt, Age 18-35yrs, BMI of 18-
30kg/m², regular menstrual cycle length of 
26-35days, basal FSH <10IU/L 
CC 100mg/d from CD3 to CD7 
Fixed 75IU/day of FSH from CD5. 
GnRH antagonist 0.25mg/day was 
initiated when the leading follicle is 
12mm and additional 75IU/day of hMG 
to initial gonadotrophins 
Long GnRH agonist for 
2weeks and then flexible 
doses of 150 - 225IU/day of 
FSH   
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Table 4: Treatment outcomes of included studies 
 
Study Primary Outcomes          Secondary Outcomes 
Live 
Birth 
Rates[LBR] 
 
Ongoing 
Pregnancy 
Rates[OPR] 
 
Number of 
oocytes 
retrieved† 
 
Total number 
of  gonadotrophins 
used per cycle§ 
 
Ovarian 
hyperstimulation 
syndrome 
[OHSS] 
 
Number of cycles 
cancelled 
 
 
Baart et al. 
2007 
Mild NR 12[19] 8.34.7 NR NR NR 
Conv. NR 7[17] 12.15.7 NR NR NR 
Blockeel et 
al. 2011 
Mild NR 10[25] 10.36.2 1177295¶ NR NR 
Conv. NR 10[27.7] 8.94.7 1364226 NR NR 
Heijnen et 
al. 2007 
Mild 70[15.8] 78[17.6] 6.94.8 1307529¶ 6[1.4] 80[18] 
Conv. 78[24] 93[28.6] 8.54.3 1832758 12[4] 27[8] 
Hohmann 
et al. 2003 
Mild NR 8[16.3] 7[1-27] ‡ NR NR NR 
Conv. NR 8[17.8] 9[1-25] NR NR NR 
Karimzade
h et al. 
2010 
Mild NR 32[32] 5.41.5 12.14.3 0[0] 4[4] 
Conv. NR 26[26] 92.2 223.6 6[6] 0[0] 
Total Mild 70[15.8] 140[20] 37.917.2 2496.1828.3 6[2] 84[16] 
Total Conv. 78[24] 144[26] 47.516.9 3218987.6 18[5.5] 27[9] 
NR=not recorded, Conv=conventional, data expressed as n [%], †data are expressed as mean  standard deviation unless stated otherwise, ‡values expressed as 
median [range], §data expressed as mean number of ampoules  standard deviation unless indicated, ¶ data expressed as mean total dose of rFSH [IU]  standard 
deviation. 
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Primary Outcomes 
 
Live Birth Rate 
Although ‘the singleton term gestation, live birth rate should be considered the best endpoint 
for ART [25,26], most studies still report live birth rates without being specific about the 
gestation, and a large proportion of them report the OPR only.  
 
One study that reported live birth rates as an outcome showed statistically significant 
difference (70/444 [15.7%] mild versus 78/325 [24%] conventional cycles) in favour of 
conventional stimulation (OR=0.59, CI:0.41-0.85, P=0.004, Figure 1a). However, cumulative 
pregnancy outcomes were comparable (43.4% in the mild regimen versus 44.7% in the 
conventional regimen). It is the only study that recorded the cumulative pregnancy rates.  
 
Ongoing Pregnancy Rate 
Five studies with a total number of 284 patients also reported a statistically significant 
difference (140/696 [20%] mild versus 144/547 [26%] conventional cycles) in favour of 
conventional stimulation for OPR per started cycle (OR=0.72, CI: 0.55-0.93, P=0.01, 
Figure1b).  
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Figure 1a:  Mild ovarian stimulation versus conventional stimulation:  Live birth rates per fresh embryo transfer 
 
 
 
 
Figure 1b:   Mild ovarian stimulation versus conventional stimulation:  Ongoing pregnancy rates per fresh embryo transfer 
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Figure 1c:   Mild ovarian stimulation versus conventional stimulation:  Ovarian hyperstimulation syndrome  
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Secondary Outcomes 
 
Ovarian hyperstimulation syndrome 
The sub-analysis of two studies showed a statistically significant reduction of 
hyperstimulation syndrome in favour of the mild stimulation (OR=0.27, CI: 0.11-0.66, 
P=0.0004, Figure 1c). No significant heterogeneity was detected between the studies. 
 
Number of oocytes retrieved per cycle and total number of ampoules of 
gonadotrophins used per cycle 
Analysed studies showed that a significantly lower number of eggs are retrieved in the mild 
stimulation protocols versus the conventional approach [37.9 ± 17.2 mild vs 47.5 ± 16.9 
conventional protocols, P=0.000] and a significantly lower number of ampoules of 
gonadotrophins are used per cycle in the mild stimulation protocols ( 2496.1 ± 828.3 vs 3218 
± 987.6 conventinal protocols, P=0.000) Table 4.  
 
Number of cycles cancelled 
The total number of cycles cancelled, including the poor follicular growth and failure to 
achieve embryo transfer, were significantly lower in the conventional protocol than in the 
mild [84 cycles in mild vs 27 cycles in conventional regimen, OR=2.55, CI: 1.62-4.02, 
P<0.0001].  
 
Cost of treatment 
Heijnen et al. also showed that the total cost of treatment is lower with mild protocol 
(difference €2412, 95% CI 703-4131) [20].  
 
DISCUSSION 
 
Over the past 30 years IVF treatment has improved, with recognizable developments in 
laboratory performance in terms of fertilization techniques, culture techniques for embryo 
development, embryo selection and cryopreservation of surplus embryos over and above 
improved ovarian stimulation protocols [27]. However, the introduction of mild stimulation 
protocols is still met with resistance in many units and the common reason is the lack of 
robust evidence to influence the current clinical practice in IVF. In this meta-analysis the 
conventional ovarian stimulation IVF showed significantly improved LBR and OPR when 
compared to mild stimulation regimens. The LBR per fresh ET from a study with a total 
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number of 148 patients (Table 4) significantly favoured conventional stimulation (OR=0.59, 
P=0.004) [20], therefore making it the treatment of choice in ART at this point.  
 
It is interesting to note that data from the study by Heijnen et al. [20] showed no significant 
difference in the cumulative LBR in both regimens (43.4% in the mild regimen versus 44.7% 
in the conventional regimen). This observation underlines the need for more randomised 
controlled trials on cumulative live birth rate comparing the two regimens. The potential value 
of the mild regimen is a reduction of complication rate in ART. We observed a significantly 
lower risk of OHSS in the mild stimulation group as also reported by a number of authors, 
suggesting this regimen as a viable strategy for the prevention of OHSS [20,28,29]. In the 
current study, it was also observed that a significantly lower number of ampoules of 
gonadotrophins were used per cycle in the mild group compared to the conventional group 
and similar findings were showed by Blockeel et al. [30]. Polinder et al. reported significantly 
lower mean direct medical costs per IVF cycle for the mild regimen (€1559 versus €1977; 
P=0.001), mainly due to lower cost of medication [31]. A similar observation was reported 
by Heijnen et al. [20]. Due to its less complex nature, fewer ampoules  of drugs and  shorter 
duration used, it has been shown that mild stimulation IVF is also associated with a 
diminished level of patient distress [32]. The above facts propose mild stimulation as an 
attractive option for a low resource setting and selected group of patients at risk for OHSS.  
 
Due to the lack of large randomised controlled trials, this meta-analysis identified and 
analysed data from prospective randomised trials conducted according to a reasonable 
standard that seek to add valuable information on the treatment outcomes in IVF stimulation 
protocols.  
 
However a notable weakness in the papers is the lack of data on live birth rates, and the 
heterogeneity amongst the different studies [Figure 1b]. An attempt was made to minimize 
the heterogeneity by maintaining strict inclusion criteria in terms of patient profile and 
indications for ART [Table 1], adherence to the definition of mild ovarian stimulation [21-23] 
in comparison to conventional ovarian stimulation, and by analysing live birth rates and 
ongoing pregnancy rates since they would be affected equally in both arms. 
 
In conclusion, this paper showed significantly better outcomes in terms of LBR and OPR per 
started cycle all in favour of conventional stimulation IVF, therefore currently remaining the 
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preferred treatment of choice. However, in the limited resource setting and in a well selected 
group of good prognosis patients, mild stimulation IVF may be considered a treatment option 
due to its potential benefits such as lower risk of OHSS, lower medication cost, less 
complexity in nature and lower levels of patient distress. In future more data on LBR in both 
mild and conventional stimulation IVF is still required for accurate scientific evaluation. 
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CHAPTER 6: SUMMARY, CONCLUSION AND FUTURE RECOMMENDATIONS 
 
The following summary and conclusion is based on extensive literature review and the 
findings of our studies, published and unpublished. 
 
THE NEED FOR ASSISTED REPRODUCTION TECHNOLOGY IN DEVELOPING 
COUNTRY LIKE OURS WITH LIMITED RESOURCES 
 
 Over 80 million couples are affected by infertility worldwide and the majority of them 
reside in the developing countries, where ART services are very scarce [1].  
 
 Severe male infertility and bilateral tubal disease caused by sexually transmitted 
infections, unsafe abortions and postpartum sepsis are main reasons for infertility in 
developing countries [2]. 
 
 Couples are prepared to risk 20% of death to achieve the goal of parenting [3].  
 
 Complicating the situation of inaccessibility to ART services in the developing 
countries, especially the sub-Saharan part of Africa, are the challenges around HIV 
and new infections. 
 
 Serodiscordant partnerships account for up to 60% of new HIV infections. [4] Similar 
findings were reported by Makwe et al. [5]. Lurie et al. have shown that 30% of stable 
heterosexual couples in South Africa are HIV-1 serodiscordant [6] and 20-50% of these 
men and women do desire children [7]. 
 
 The dilemma of high risk behaviour motivated by this strong desire to reproduce 
becomes a realistic challenge, and it does exist [8,9]. 
 
 In 2010, the Minister of Health, Dr Aaron Motsoaledi, reaffirmed his commitment to the 
priorities of the National Department of Health Ten-Point plan to improve service 
delivery, and one of the Department’s major targets was the reduction of new HIV 
infections by 50% by 2014 (target is missed but the battle must continue) [10].  
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 There were lost opportunities to focus on reduction of sexual HIV transmission. The 
emphasis was on prevention of mother-to-child transmission (PMTCT). Urging health 
care providers to actually communicate and preach safer conception strategies 
including early initiation of antiretroviral therapy and appropriate utilization of assisted 
reproductive technologies, did not receive the same emphasis [11,12].  
 
 There is only 6% coverage of ART needs in South Africa (SA) because ART is an 
expensive treatment, unaffordable and still very much inaccessible to many [13]. A 
cycle of IVF in private clinics in South Africa will cost the individual couple 
approximately R35 000 - R50 000 (2 702-3 861 USD) [14] and the cost drivers are 
mainly medication (28%), clinicians’ fees and consultation (29%), and laboratory fees 
(35%) [14]. The cost of an IVF cycle is also reported to account for 52% of an individual 
couple’s average disposable income [15]. 
 
Based on the above-mentioned facts and knowledge of the cost drivers in IVF, the objective 
was to develop a model that can focus on lowering the cost of treatment and make it 
accessible to more patients. This is how the thesis with the theme “Low cost IVF Strategies” 
was conceived.  
 
The robust literature search and the findings of the thesis highlighted the following aspects 
to consider when establishing affordable ART:   
 
Understanding the physiology of folliculogenesis - Chapter 1 
 
Of the three theories of follicular recruitment, continuous recruitment which suggests that 
small antral follicles of ≤4-6mm are recruited to grow continuously at all stages of 
reproductive life independent of gonadotropin support [16], might substantiate the mild 
ovarian stimulation regimen rationale of late introduction of gonadotropins in IVF/ICSI cycle 
and discontinuation a day or two prior to HCG administration in non-pituitary suppression 
cycles – thereby significantly lowering the total amount of gonadotropins required and hence 
the cost of medication. Furthermore, the duration of the rise in FSH above the critical 
threshold determines the number of dominant follicles selected from the recruited cohort. 
This phenomenon is termed the “FSH Threshold” or “FSH Window” or “FSH gate” [17]. 
During ovarian stimulation therapy, prolonging the FSH window allows multiple follicles to 
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be selected, illustrating again that it might not necessarily be about the quantity of 
gonadotropins required but the length of exposure. This is a very important concept in mild 
ovarian stimulation, especially in good prognosis patients (normal endocrine profile and 
women of young age, < 35yrs).  
 
Establishing the role of inexpensive and safe oral medication, Clomiphene Citrate as 
the ovulation induction agent in assisted reproductive technology - Chapter 2 
 
Clinical pregnancy rates in IVF cycles of normal responders using CC alone could vary from 
16% per started cycle to 34% per ET [18-21]. In women with poor ovarian response or 
compromised ovarian reserve, the use of CC alone in IVF has been associated with 
pregnancy rates of 5-10% [22,23]. Although the rates were low, they were comparable to 
those of women treated with conventional long GnRH agonist protocol and large amounts 
of gonadotropins [23], thereby making CC alone IVF a cheap reasonable option for women 
with depleted ovarian reserve, both young and old. The introduction of gonadotropins, either 
alone or in combination with oral agents, was introduced in IVF with the aim to achieve an 
increased number of oocytes for fertilization [24]. Subsequently, several studies using 
combination therapy reported acceptable clinical pregnancy rates per ET of 32-43% [25-29]. 
However this treatment regime is reported to be associated with high rates of premature LH 
surge (approximately 27%) and significantly high cancellation rates, ranging between 15-
30% [30,31]. Our randomised controlled trial in Chapter 3 of this thesis (below) reported 
similar findings of high premature LH surge in CC plus gonadotropin ART treatment. The 
effective method of preventing premature LH surge in ART cycles is pituitary gonadotropin 
suppression using a GnRH agonist (long, exhausting and expensive) or GnRH antagonist 
(short and relatively cheap) as explained in Chapter 2. In poor resource settings these 
methods will remain unaffordable because they require an increased number of 
gonadotropins at a high cost. Proposed, less expensive but effective methods are published 
in the literature, but the limitations of the studies were old data, small sample sizes and 
heterogeneous data with different outcomes. They include pre-treatment with oral 
contraceptives and prolonged use of CC during ovarian stimulation [19,32]. We therefore 
performed a randomised controlled trial to evaluate the use of prolonged CC as a method 
of preventing premature LH surge in ART programmes (protocol outlined below). In addition, 
progesterone (Medroxyprogesterone acetate, Utrogestan) and antiprogestin (Mifepristone) 
have also been proposed as effective oral alternatives for the prevention of premature LH 
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surge in women undergoing controlled ovarian hyperstimulation [33-35]. This is based 
largely on animal model studies which demonstrated that progesterone (P) successfully 
blocks the E2-induced LH surge in both follicular and early luteal phase of rhesus monkeys 
and ewes when started early in the follicular phase of the menstrual cycle [36,37]. It is worth 
mentioning that in all progesterone studies the endometrial thickness was not critically 
analysed during the stimulation protocol and the embryos were cryopreserved and 
subsequently followed by frozen thawed embryo transfers, therefore calling for further 
evaluation of this protocol with a closer look at the endometrium and outcomes if fresh 
embryo transfer is to be performed. 
 
A simple method of an extended 8-day course of Clomiphene Citrate versus a 5-day 
course in an attempt to suppress premature luteinizing hormone surge in an assisted 
reproductive technology programme: a randomized controlled trial - Chapter 3 
 
The purpose of the study was to evaluate the simplified and inexpensive method of 
preventing premature LH surge in ART treatment.  
 
Treatment protocol 
The patients were randomised into one of two treatment groups using a simple 
randomization schedule assigned via numbered sealed envelopes following patient 
assessment. 
 
In Group A, the patients were stimulated with CC (Fertomid, Cipla MEDPRO RSA) 100mg 
for five days from cycle day 3 to 7. hMG (Menopur, FERRING, SA) 150-225IU was added 
on cycle day 4, 6, 8 and/or 10. 
  
In Group B, patients were stimulated with CC (Fertomid, Cipla MEDPRO RSA) 100mg for 
eight days from cycle day 3 to 10. hMG (Menopur, FERRING SA) was added on cycle day 
4, 6, 8 and/or 10. No baseline endocrine biochemical testing was performed in either group. 
Ultrasound was performed in both groups on cycle day three for AFC and evaluation for any 
cyst formation. The subsequent ultrasound was performed on cycle day 8 or 9 and thereafter 
according to follicular growth. LH was assessed from cycle day 9 and if negative, performed 
on alternative days until the day of hCG administration (Ovitrelle 250µg/0.5ml, Merck SA). If 
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LH positive, the oocyte retrieval would be performed within the next 24 hours. hCG (Ovitrelle, 
Merck SA) 250µg/0.5ml was administered when there was a leading follicle of >18mm. 
 
In this study we found the rates of premature LH surge to be high with 20% (5-day 
Clomiphene group) versus 24% (8-day Clomiphene group). The cycle cancellation rates 
were also high, 36% (5-day CC group) vs 31% (8-day CC group). The main reason for 
cancellation was failed embryo transfers as a result of poor embryo development and 
growth, which may strongly suggest a negative impact of premature LH surge on the quality 
of oocytes. However, cycle cancellation as a result of poor follicular development occurred 
in 10% (5-day CC arm) and 11% (8-day CC arm) of the cases. Our study could not replicate 
the findings of previous studies looking at a low dose CC of 50mg as a strategy to prevent 
premature LH surge in IVF/ICSI cycles. Perhaps the populations studied were different and 
the methodology also differed. We were not concerned that, not prolonging the duration of 
CC further by a day or two until the day of hCG trigger as suggested in previous studies, 
would affect the anti-oestrogenic properties of the drug on the pituitary and lose the benefit 
of lowering the LH and subsequent prevention of LH surge. More so, it is unclear how long 
it thus takes for CC (enclomiphene & zuclomiphene) to metabolise and clear from the 
system. Our study concluded that prolonged use of CC was not associated with a reduction 
of premature LH surge in mild ovarian stimulation ART programmes, therefore 
recommending other affordable methods of suppressing premature LH surge such as pre-
treatment with a oral contraceptive pill [19] and the use of progesterone and FET cycles [33-
35] to be explored and evaluated in large clinical trials. In addition, the need to further 
evaluate the use of low dose CC until the day of hCG [38] or the use of tamoxifen at a dose 
of 40mg from cycle day 3 until the day of hCG (with positive stimulating effect on 
endometrium when compared to CC) [39] with or without the use of non-steroidal anti-
inflammatory drugs such as indomethacin to prevent spontaneous follicular rupture [40], will 
still be necessary in larger studies.  
 
During the trial we observed a clinical pregnancy rate per ET and LBR per ET of 24% and 
16% respectively. We believed the outcomes were acceptable for a mild stimulation protocol 
but wanted to know at what cost and whether the model we were using could be a solution 
towards making ART accessible to sub-fertile couples in resource restricted settings. This 
question led to the description and evaluation of the PPI model outlined below. 
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Description and implementation of the Public-Private Interaction model - Chapter 4 
 
This is a structured model that began with the willingness and commitment of the 
administration of Tygerberg Hospital and Stellenbosch University (public sector) and the 
caring and generous involvement of the Drs Aevitas Institute for Reproductive Medicine 
(private sector) with an altruistic intention to help (Addendum A). This is the vision that 
tertiary institutions must have, to establish strong and positive relations with private facilities 
for the benefit of patients or communities (service delivery) and students at large (research, 
training and teaching).  
 
 Infrastructure development can be made possible by the public sector. This is a 
significant and costly component of ART services. The minimum amount of space 
required is approximately a two-bedroom area of 120 m2 to provide adequate service. 
This small area of space can be identified within the hospital building, ideally close to 
areas with easy access to resuscitation facilities such as an operating theatre. 
Andrology services can be integrated within the IVF set-up.  
 
 Equipment: Essential equipment for basic ART services includes: (Addendum B)  
 
o Incubator  
The equipment was acquired through the Stellenbosch University grant. This is a 
notable contribution by the university as they understood our mandate to continue 
research, teaching and training of sub-specialist fellows, registrars, honours and 
masters reproductive biology students. 
 
o ICSI micromanipulator  
The machine was donated by the Drs Aevitas private clinic, which was a significant 
contribution considering the current cost of the equipment (approximately 
R500 000). 
 
Contributions of such magnitude lay a strong foundation in the establishment of 
specialised services such as IVF/ICSI treatment in the public sector services.  
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 Personnel: Competent staff, both clinicians and embryologists, are the essential 
components of successful ART services [41]. Staff remuneration contributes 30% to 
the cost of IVF in the private setting [14]. In the PPI model, the clinicians and the 
embryologists are employed either by the provincial government or by the university, 
primarily for service delivery and research, training and teaching respectively. They 
therefore incorporate extended ART services within the day-to-day routine of their 
duties. In this model, there are no IVF sisters or co-ordinators, which makes the model 
cheaper but adds a lot of strain on the clinicians and the scientists alike, who have to 
assume those responsibilities. Under current circumstances and limited resources the 
system is functional and can be sustained.   
 
 Stimulation protocol: A mild ovarian stimulation protocol was adopted in this model 
as another strategy to lower the cost of IVF/ICSI treatment. It is defined as the method 
when FSH or HMG is administered at lower doses, and/or for a shorter duration in a 
GnRH antagonist co-treated cycle, or when oral compounds (anti-oestrogen or 
aromatase inhibitors) are used either alone or in combination with gonadotrophins with 
the aim to collect a smaller number of oocytes [42-44]. The anti-oestrogens include CC 
and/or tamoxifen. 
 
We used CC because it is cheap, well studied and because of its safety profile. We 
have observed reasonable pregnancy outcomes in CC IVF cycles without the use of 
mid-cycle antagonists. (Mentioned and discussed in detail in Chapter 2.) 
 
The decision to use hMG, Menopur in the treatment protocol was based on the drug’s 
effectiveness and relatively low cost in comparison to other gonadotropins [45]. 
 
With regard to cycle monitoring, it is cheaper and safe to use the ultrasound and urinary 
LH test only without adding serum biochemical tests because there is no proven 
significance of the additional tests in terms of improvement in IVF outcomes [46,47]. In 
a mild ovarian stimulation the risk of hyperstimulation is very low [44] and further 
supporting less intense monitoring.  
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 Laboratory: Further illustration of the PPI benefit is in the laboratory section of ART 
services: 
o Large private clinics purchase media, plastics and other consumables in bulk and 
the small units like Tygerberg unit (public) access these consumables at a 
reasonably lower  price (manufacturer’s price)  from them. 
 
o The aspiration needles and embryo transfer catheters received from the private 
clinic following a single usage are sterilized according to medical devices 
sterilisation and safety standards [48] and re-used to further lower the costs of 
treatment. Following the once-only repeat use of these devices, they were then 
discarded. The sterilization of medical equipment is generally an accepted practice 
also seen in operating theatres [48]. 
 
o The egg retrieval is performed under conscious sedation and local anaesthesia, 
without the need for general anaesthesia and theatre, further reducing the cost of 
treatment significantly. In a limited resource setting, the method does not interfere 
with other services because it does not utilize or remove the hospital’s anaesthetist 
or nursing sisters from their assigned duties. The medication is administered by the 
clinician performing the procedure and there is always a supporting clinician on 
standby if necessary. The duties of the nursing sister are performed by the 
embryologist in the laboratory.   
 
We have observed CPR per ET and LBR per ET of 23.5% and 17.7% respectively which 
are low when compared to conventional IVF outcomes (SARA report) [13]. The study has 
also shown that in women ≤35yrs of age the clinical pregnancy rates per ET were 25.4% vs 
40% of conventional IVF data from the South African Registry of Assisted Reproduction 
Technologies, SARA (12 IVF clinics contributed to the registry) [13]. Women >35yrs of age 
had pregnancy rates also significantly in favour of conventional IVF with 29.6% vs 18.9% 
from our study [13]. These findings were also observed by the meta-analysis we performed 
(Chapter 5) [49], which presents strong evidence in favour of conventional stimulation IVF 
and therefore suggests that it be considered a treatment of choice for patients requiring IVF 
treatment. The challenge is the cost of single IVF/ICSI treatment [14]. In our analysis 
(Chapter IV, Table 5) we established that the direct cost of one conventional IVF to a couple 
is approximately R51 000 (USD 3 938) vs R7 291 (USD 563) in the private vs public sector 
respectively.  We also observed that the probability of better outcomes (CPR >30%) in a low 
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cost model will require a repeated number of treatment cycles (at least three attempts). What 
is not clear in the SARA report was the number of individual cycles required to achieve the 
reported pregnancy rates [13]. 
 
Another notable finding of the study (Chapter 4, Table 4) was to show that 237 participants 
started the first cycle of treatment but only 37 participants were able to attempt the third 
cycle of treatment. The main reason for the significant decline was lack of funds. This gave 
us an impression that the model gave access to many couples who would have not have 
had any opportunity to attempt parenthood, but left a big question mark as to whether the 
treatment is affordable or not. – further proposing an economical model in our setting to 
assess at what cost ART can be declared affordable. This is an analysis which we plan to 
undertake in collaboration with the Health Economics Division of the Department of Health. 
 
In conclusion, the PPI between Tygerberg Academic Hospital, Stellenbosch University 
(public entities) and Drs Aevitas Institute for Reproductive Medicine (private facility) is a 
model that has made ART services more available to the infertile community of the Western 
Cape. Because of its relatively low cost, it has attracted patients from all over South Africa 
and Sub-Saharan Africa (Malawi & Zambia) who are desperate to be parents but cannot 
afford the private fees. We believe the model has achieved the primary goal of making ART 
accessible based on the number of requests we receive on a daily basis from both HIV 
negative and positive patients. We aim to promote the model to other institutions in South 
Africa and Africa as a whole and hopefully to reduce the burden of the disease, improve 
access to treatment and offer overall improvement in quality of life of people living with 
infertility in the continent. For a central academic hospital embarking on ART services but 
limited by resources, a qualified reproductive specialist and embryologist are mandatory to 
begin with. Basic infrastructure is essential (small room within the hospital envrironment). 
Regarding equipment, mobilization of the private sector could be a valuable exercise to 
purchase a basic incubator and a microscope, and the service can then be rendered (page 
152, Figure 3). However there is also ongoing research to explore the effectiveness of 
simple embryo culture systems such as the INVO cell or the walking egg tWE system (page 
102). The centres can also be supported through outreach programmes.  
 
Overall, this thesis has demonstrated that there is a role for minimal ovarian stimulation 
protocols (Literature review in Chapter 2 & RCT in Chapter 3) together with other cost saving 
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strategies (Descriptive PPI study in Chapter 4) for people living in low income countries with 
limited resources. However, there must be an effort and innovative strategies to further 
improve pregnancy outcomes per cycle of IVF/ICSI treatment started. As shown by the 
findings of our meta-analysis (Chapter 5) that pregnancy rates per cycle are still significantly 
higher with conventional IVF, patients with associated endocrine abnormalities such as 
PCOS, or those with endometriosis, should be advised appropriately regarding the 
outcomes of different regimens.  
 
Ethically and generally speaking, the couples should be provided with options and adequate 
information regarding the outcomes of ART treatments in order to make an informed 
decision. In that way the aim to provide equal access to good quality health care could be 
achieved. 
 
FUTURE RECOMMENDATIONS 
 
 PPI is a feasible model to improve the provision of health care in resource-restricted 
settings – it should be pursued and implemented where necessary.  
 Commitment, vision and political willingness are fundamental pillars towards improving 
access to health care and ART in particular for the benefit of improving access to 
fertility treatment. 
 Mild ovarian stimulation protocols should be encouraged especially in good prognosis 
patients and in limited-resource countries.  
 However, the effort through research should continue to identify strategies that 
optimise the outcomes in these regimes by means of acceptable pregnancy rates, 
lowering the risk of premature LH surge and cycle cancellations.  The methods should 
be effective and affordable as well.  
 Investing in competent personnel is also instrumental towards successful 
implementation of health services in general and also specialised services such as 
ART. The clinicians and embryologist must form part of the broader base of the hospital 
staff members, thereby providing services other than ART. 
 Further laboratory strategies that aim to reduce the costs of IVF treatment and improve 
access may include the “The Walking Egg” (tWE) project [50] and the INVO cell 
devices [51]. However the methods need to be evaluated in large clinical trials. We are 
embarking on participating in a multi-centre trial to answer some of these questions.  
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 Other methods of affordable IVF such as uterine-sperm and egg transfer (U-SET) 
should also be evaluated in large clinical trials [52]. 
 Figure 3 below illustrates the three basic pillars of implementing IVF services and the 
impact of the PPI model in facilitating and enabling the process.     
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Figure 3: Basic IVF Implementation triangle illustrating the PPI model† 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*The Walking Egg project (tWE) using simplified embryo culture system and the INVO Cell device 
still to be evaluated in large multi-centre clinical trials and hopefully be integrated as part of routine 
method of treatment in any simplified IVF/ICSI cycle (both in developing and developed countries).  
 
It is important and necessary that the private sector at large, not necessarily the ART clinics, 
should be given an opportunity to participate and get involved with community building 
projects and projects that seek to facilitate academic development and strengthening 
through corporate social initiatives.  
 
www.youtube.com/watch?v=V0ts4aC-GsY 
 
www.bbc.co.uk/news/health-27256416  
   
INFRASTRUCTURE 
Governmental commitment and hospital leadership – 
Provision of the clinic and laboratory facilities within the 
existing hospital structures† 
 
PERSONNEL & STIMULATION 
PROTOCOL 
Government & University engagement  
 Fertility specialist & embryologist 
employed at a cost to provincial 
hospital and the university† 
 Mild ovarian stimulation protocol – 
cheaper & simpler with less 
monitoring needs 
EQUIPMENT & LABORATORY 
Combined Public & Private commitment    
 Sponsored Incubator & ICSI 
micromanipulator (very expensive 
items)† 
 Enabling access to consumables at a 
cheaper price† 
 Simplified oocyte retrieval technique 
 Simplified embryo culture systems* 
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Addendum B: Basic IVF/ICSI equipment   
 
 CO2 Incubator   
  
 Microscope – ordinary 
 
 Laminar flow 
 
 Refrigerator 
 
 Centrifuge 
 
 Media preparations 
 
 Cryopreservation systems (simple freezing method) 
 
 Micromanipulator 
 
 Clean room (filters, positive pressure, stainless steel equipment) 
 
 Heated stage 
 
 Necessary consumables (oocyte retrieval, sperm preparation, insemination 
techniques, fertilization media, embryo culture media, and embryo transfer).   
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